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1 Summary 
 
The elimination of virus-infected cells to block viral spread is substantially conveyed 
by effector CD8+ T cells. Trafficking of naïve T cells into the lymph node is a crucial 
step for their activation to effector T cells. The entry into the lymph nodes is mediated 
by several cell adhesion molecules that are highly specific for given lymph nodes. 
For the ingress into the gut-associated lymphoid tissue (GALT) such as mesenteric 
lymph nodes and Peyer’s patches, the integrin α4β7 is the major homing receptor that 
interacts with its main ligand MAdCAM-1. On naïve T cells, α4β7 is expressed at low 
level, however upon activation in the GALT its expression is significantly upregulated 
on effector T cells. Consequently these effector T cells migrate into the 
gastrointestinal tract, where MAdCAM-1 is also expressed.  
The migration patterns of virus-specific CD8+ T cells upon viral infection have been 
studied in detail. In contrast, the migration of the major population of virus-unspecific 
CD8+ T cells, i.e. bystander-activated T cells is poorly understood. In our study, we 
aimed to determine how trafficking of these non-cognate, bystander-activated T cells 
is affected upon viral infection.  
We discovered that α4β7 expression was negatively regulated on bystander-activated 
CD8+ T cells upon injection of poly (I:C), which imitates innate immune activation 
upon viral infection. This effect was also observed for viral infections such as Sendai, 
EMCV and the mutant form of VSV virus. Furthermore, we scrutinized the direct role 
of IFN-α on T cells to exert α4β7 modulation. In the case of EMCV infection, IL-6 
played a dominant role in the alteration of α4β7 expression. Finally, using an adoptive 
transfer model we could prove that the downregulation severely impacted the 
trafficking of T cells into the Peyer’s patches and to a lesser extent into the 
mesenteric lymph nodes.  
These findings demonstrate that a mechanism to regulate trafficking of 
bystander-activated T cells during viral infection exists and that this is controlled by 
the induction of cytokines such as IFN-α and IL-6. We hypothesize that the 
downregulation of α4β7 on naïve T cells functions 1) to allow space for virus-specific 
effector T cells to expand in the GALT and 2) to exclude bystander-activated T cells 
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from the GALT in order to prevent mistrafficking, which could cause autoimmune 
diseases.  
Zusammenfassung 
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Zusammenfassung 
 
T-Zellen spielen eine essentielle Rolle im Aufbau der adaptiven Immunität. 
Die Migration von naiven T-Zellen in die Lymphknoten ist ein notwendiger Schritt für 
ihre Aktivierung zu Effektor-T-Zellen. Der Eintritt in die Lymphknoten wird durch 
verschiedene Zelladhäsionsmoleküle vermittelt, die hochspezifisch für bestimmte 
Lymphknoten sind. Für den Zugang in das darmassoziierte lymphatische Gewebe 
(GALT), wie mesenteriale Lymphknoten und Peyer-Plaques, ist das Integrin α4β7 der 
Hauptrezeptor, der mit seinem Ligand MAdCAM-1 interagiert. Auf naiven T-Zellen ist 
das Integrin α4β7 schwach exprimiert, jedoch wird es bei einer T-Zell-Aktivierung in 
GALT hochreguliert. Folglich wandern die Effektor-T-Zellen in den gastrointestinalen 
Trakt, in dem MAdCAM-1 ebenfalls exprimiert ist. Die Eliminierung von 
virus-infizierten Zellen zur Hemmung der Ausbreitung von Viren wird wesentlich von 
Effektor-CD8+-T-Zellen durchgeführt. 
Während viele Studien über die Migration von virus-spezifischen CD8+ T-Zellen 
bereits bekannt sind, wurde die Migration der überwiegend virus-unspezifischen 
aktivierten CD8+ Population bisher nicht detailliert untersucht. In unserer Studie ist 
das Ziel die Feststellung, ob die Migration dieser unspezifisch-aktivierten T-Zellen 
während einer viralen Infektion verändert wird.  
Durch unsere Experimente konnten wir zeigen, dass die α4β7 Expression auf 
unspezifisch-aktivierten T-Zellen bei einer Stimulation mit poly (I:C), die virale 
Infektion nachahmt, negativ reguliert wird. Diesen Effekt konnten wir auch in anderen 
viralen Infektionen mit Sendai, EMCV und einem mutierten VSV-Stamm beobachten. 
Des Weiteren konnten wir beweisen, dass IFN-α auf die T-Zellen eine direkte 
Funktion zur Regulierung der α4β7 Expression ausübt. Im Falle einer EMCV Infektion, 
spielt IL-6 eine beträchtliche Rolle in die Herabregulation der α4β7 Expression. 
Letzendlich konnten wir durch ein Adoptiv-Transfer-Experiment bestätigen, dass die 
α4β7 Runterregulation auf die Migration der unspezifisch-aktivierten T-Zellen in den 
Peyer-Plaques und zum Teil in den mesenterialen Lymphknoten eine gravierende 
Auswirkung hat. 
Unsere Studie hat damit gezeigt, dass ein Mechanismus zur Regulierung der 
Migration von unspezifisch-aktivierten T-Zellen während einer viralen Infektion 
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existiert und diese durch induzierte Zytokine wie IFN-α und IL-6 beeinflusst wird. 
Wir vermuten, dass die α4β7 Runterregulation auf naiven T-Zellen nachstehende 
Funktionen hat. Erstens, erlaubt es den virus-spezifischen Effektor-T-Zellen in den 
Lymphknoten zu expandieren. Zweitens, ist es möglicherweise eine 
Präventionsmaßnahme, damit die unspezifisch-aktivierten T-Zellen nicht 
versehentlich in den Darm geleitet werden, was zu einer Autoimmunerkrankung 
führen könnte. 
 
Introduction 
 
5 
2 Introduction 
2.1 Aim of thesis  
 
The integrin α4β7 is an essential cell adhesion molecule that allows naïve T cells to 
enter gut-associated lymphoid organs (GALT) such as Peyer’s patches and 
mesenteric lymph nodes. Moreover, it also plays an indispensable role in migration of 
effector T cells activated in the GALT into the gastrointestinal tract. Since α4β7 is 
known to play a role in many diseases such as HIV infection (Arthos et al., 2008), 
and graft-versus-host-disease (Waldman et al., 2006) and inflammatory bowel 
diseases (Rivera-Nieves et al., 2005), it is crucial to understand how this integrin is 
regulated.  
It has been established that upon activation by antigen-presenting cell in the GALT, 
the antigen-specific activated T cells increase the expression of α4β7 in order to gain 
access into the gastrointestinal tract, where the antigen of the intruders comes from 
(Johansson-Lindbom et al., 2003). However, how migration of antigen-unspecific 
(bystander) activated T cells is governed has been poorly studied. The first evidence 
that migration of bystander-activated T cells is also controlled during bacterial 
infection, was delivered by our colleagues in the lab, Simon Heidegger, Sophie 
Kirchner and colleagues (Heidegger et al., submitted). They demonstrated that upon 
Salmonella typhimurium infection α4β7 expression on naïve T cells is decreased. 
They could also show that this effect can be mimicked when using TLR ligands and 
that the downregulation interfered with the ability of naïve T cells to enter the GALT. 
Furthermore, upon presence of TLR ligands and ovalbumin (OVA) as specific 
antigen, they could prove that T cells recognizing OVA (OT-I T cells) in the GALT 
increased their α4β7 expression as previously described, whereas wild-type T cells 
did not.  
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Whereas these studies have started to scrutinize the regulation of α4β7 expression on 
naïve T cells during bacterial infection, we next questioned how α4β7 is altered during 
viral infection. In the first part of this thesis, poly (I:C), a TLR3 ligand that imitates 
viral infection, was utilized to answer following questions:  
1. Does α4β7 expression on naïve T cells change after poly (I:C) injection? 
2. Which cytokines play a role? 
3. How is the migration of these naïve T cells impaired?  
 
In the second part of this thesis we intended to overexpress α4β7 on T cells. T cells 
are essential for the direct killing of tumor cells in a high-specificity manner. However, 
in tumor-bearing patients T cells are often incapable of conducting their function due 
to 1) immunosuppressive microenvironment in the tumor, 2) failing in recognition of 
the tumor cells or 3) the absence of their specific-directed migration into the tumor. In 
this case, one possibility is to genetically modify T cells of tumor patients in vitro and 
transferred them back into the patient, referred to as adoptive T cell therapy. 
Adoptive T cell therapy has been used for treating tumors, where the infiltration 
number of the effector T cells into the tumor typically correlates with the success of 
tumor eradication and prolonged survival (Galon et al., 2006). Our studies in gastric 
tumors have revealed that transferring T cells of immunized mice into tumor-bearing 
mice was effective to reduce subcutaneous tumor size correlating with a high 
infiltration of effector T cells. However, the T cells were not able to enter the gastric 
tumor of the same mice due to the microenvironment in the tumor. Hence, they failed 
to execute their function in the tumor (Bourquin et al., 2010). We therefore aimed to 
overexpress α4β7 on T cells to improve the targeting into gastrointestinal tumors.  
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2.2 T cell migration  
 
T cells are one of the most motile cells in the body that constantly recirculate into 
secondary lymphoid organs. They belong like B cells to the secondary defense 
system, the adaptive immunity, which is linked to the activation of the innate 
immunity, the primary defense system. T cells have broad functions and tasks 
including elimination of virus-infected cells and tumor cells, potentiating immune 
response and activation of B cells. To exert their functions, T cells firstly need to be 
activated by an antigen-presenting cell (APC), which comprise the innate immune 
cells such as dendritic cells (DC) and macrophages, but also B cells. These cells are 
capable of presenting chopped short peptide fragments of intruders such as bacteria 
and virus (antigen) on their cell surface with the help of the majorhistocompatibility 
proteins (MHC class I, II). These peptides within the MHC proteins are recognized by 
T cells, which possess the right T cell receptor (TCR). 
T cells are generated in the bone marrow as immature cells termed thymocytes. The 
maturation takes place in the thymus in which they migrate to. Following sequential 
selection mechanisms, cells that pass the negative and positive selection process, 
differentiate either into CD4+ or CD8+ T cells. At this time point, these mature T cells 
are referred to as naïve T cells because they have not yet encountered their specific 
antigen. In adults, naïve T cells consist of 25 million to 100 million distinct clones 
(Arstila et al., 1999). After their maturation in the thymus, these naïve T cells begin to 
traffic into the blood stream and enter the secondary lymphoid organs, where they 
eventually meet their cognate APC with the specific antigen. However, only a very 
small percentage of these naïve T cells (several thousand T cells) will obtain the 
opportunity to recognize their individual antigen (Von Andrian and Mackay, 2000).  
The entry from blood vessels into the secondary lymphoid organs requires multistep 
adhesion cascades that are tightly governed by a plethora of distinct cell adhesion 
molecules (Springer, 1994; von Andrian and Mackay, 2000). The preferential 
migration into specific tissues is referred to as homing (Butcher and Picker, 1996).  
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2.2.1 Homing of naïve T cells into secondary lymphoid organs is mediated by 
multistep adhesion cascades 
 
Unlike the migration into the spleen, the homing of T cells from blood vessels into the 
lymphoid organs such as peripheral lymph nodes, gut-draining mesenteric lymph 
nodes and Peyer’s patches (lymph nodes along intestine), is an active process that 
requires the interaction between cell adhesion molecules and their ligands. These 
ligands, also termed adressins, are constitutively expressed on specialized 
endothelial venules, the so-called high endothelial venules (HEV) that function as the 
gateway into the lymphoid organs (Girard and Springer, 1995). Most cell adhesion 
molecules and adressins belong to four families of proteins: the selectin family, the 
mucin-like family, the immunoglobulin superfamily and the integrin family (Elangbam 
et al., 1997).  
To enter the lymph nodes, T cells must initiate the adhesion into the HEVs (Table 1). 
This process is called tethering and rolling (step 1). Receptors responsible for 
tethering and rolling are also referred to as homing receptors and their ligands are 
termed vascular addressins (Berg et al., 1989). For the tethering onto the HEVs, 
T cells engage the constituvely expressed L-selectin that binds to peripheral-node 
addressin on HEV of peripheral lymph nodes (Berg et al., 1992; Kansas, 1992). 
However, the adhesion bond between L-selectin and peripheral-node addressin is 
non-permanent and keeps disassociating and reassociating upon pressure of flowing 
blood causing the rolling motion.  
To stop rolling, T cells need to receive signals to activate their secondary receptors 
(activation, step 2). These receptors belong to the integrin family, which are 
characterized as heterodimeric non-covalently-linked proteins consisting of an α and 
a β chain. To date, eighteen α subunits and eight β subunits have been characterized 
forming 24 integrins in vertebrates (Zhang and Wang, 2012). Integrin members 
expressed on leukocytes include two β2 integrins (LFA-1 or αLβ2 and αMβ2) and two 
α4 integrins (α4β1 and α4β7) (Marelli-Berg et al., 2008). The ligands of the integrins 
are the members of immunoglobulin superfamily comprising mucosal addressin-cell 
adhesion molecule type 1 (MAdCAM-1); vascular-cell adhesion molecule 1; 
intracellular adhesion molecule 1 or 2 (Osborn et al., 1989; Kita et al., 1992; Briskin 
et al., 1993). 
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The signal activation for the integrins is provided by distinct chemokines immobilized 
on the endothelial cell surface that are capable to activate their corresponding 
chemokine receptors (Rot and Von Andrian, 2004). On the HEVs of secondary 
lymphoid organs, CCL19 and CCL21 are responsible for the interaction with CCR7 
on T cells (Yoshida et al., 1997, 1998). The binding of the chemokine to its receptor 
induces a signal transmission through the so-called G-proteins causing 
conformational changes and higher affinity of the integrins to their ligands. As a 
consequence, a firm adhesion to the endothelium can be established, a process 
called arrest (step 3). For the arrest on HEVs of peripheral lymph nodes, LFA-1 on 
T cell binds to its ligand ICAM-1 or ICAM-2 (Marlin and Springer, 1987; Staunton et 
al., 1989). The last step is the transendothelial migration (step 4), which is the entry 
process of the T cell into the lymph node. This migration mainly occurs through 
endothelial cell junctions, also referred as to the paracellular route (Schoefl, 1972). 
An alternative way is the migration through the body of endothelium, the transcellular 
route (Cho and De Bruyn, 1981; Engelhardt and Wolburg, 2004).  
In contrast to migration into peripheral lymph nodes, trafficking to the GALT 
comprising mesenteric lymph nodes and Peyer’s patches is predominantly mediated 
by the integrin α4β7 which is expressed on various type of immune cells (Postigo et 
al., 1993; Schweighoffer et al., 1993; Erle et al., 1994). α4β7 mediates tethering, 
rolling and arrest by binding to its major ligand MAdCAM-1 expressed on HEVs of 
mesenteric lymph nodes and Peyer’s patches (Nakache et al., 1989; Berlin et al., 
1993). It has been demonstrated that formation of mesenteric lymph nodes, but 
mostly of Peyer’s patches, is severely impaired in β7-deficient mice due to the homing 
defect into these organs (Wagner et al., 1996). To note, it has also been reported 
that L-selectin can still mediate tethering and rolling into the mesenteric lymph nodes 
and to a lesser extent also into Peyer’s patches by binding to the modified 
glycosylated MAdCAM-1 (Berg et al., 1993; Arbonés et al., 1994).  
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 Inductive site 
Target tissue Lymph node Peyer’s patches 
Tethering/rolling L-selectin/PNAd (in PLN) 
α4β7 /MAdCAM-1 (in MLN) 
α4β7 or L-selectin/ 
MAdCAM-1 
Integrin activation CCR7/CCL19, CCL21 CCR7/CCL19, CCL21 
Firm adhesion LFA-1/ICAM-1, ICAM-2 α4β7 /MAdCAM-1  
LFA-1/ICAM-1, ICAM-2 
Table 1: Homing cascade that direct naïve T cells to lymph nodes (adapted from von Andrian 
and Mackay, 2000). 
 
2.2.2 T cells activated in the GALT acquire gut-homing specificity 
 
After homing into the GALT, T cells might eventually interact with an activated DC 
carrying antigens of the pathogen (Randolph et al., 2005). By chance, a few naïve 
T cells recognize the antigen presented by the DC leading to their activation and 
clonal expansion. Depending on the expression of CD4 or CD8 on the naïve T cells, 
the activated naïve T cells differentiate into T helper cells (Th cells) or cytotoxic T 
cells (CTL), respectively. Whereas Th cells are important in producing cytokines and 
activating other immune cells such as B cells, CTL and macrophages, CTLs are 
directed to eliminate infected cells or tumor cells that display the same antigen as the 
activating DC.  
To exert their functions, the recently activated effector T cells need to egress from 
the lymphoid organs and move to the specific peripheral tissue where the antigen 
has been captured by the DC. These T cells acquire a new distinct repertoire of cell 
adhesion molecules depending upon where they are activated. For example, it has 
been shown that T cells activated in peripheral lymph nodes are imprinted to express 
E-selectin, P-selectin, CCR4 and CCR10, which are important for the homing to the 
skin (Picker et al., 1991; Campbell et al., 1999; Morales et al., 1999; Reiss et al., 
2001; Mora and von Andrian, 2006).  
In contrast, antigenic stimulation with DCs from Peyer’s patches or mesenteric lymph 
nodes in the presence of antigen, adjuvant or anti-CD3 antibody enhances the 
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expression of α4β7 and CCR9 on T cells (Stagg et al., 2002; Johansson-Lindbom et 
al., 2003; Mora et al., 2003). Consequently, these T cells are licensed to migrate into 
the gastrointestinal tract. Besides being expressed on the HEVs of Peyer’s patches 
and mesenteric lymph nodes, the α4β7 ligand MAdCAM-1 is also expressed on the 
intestinal and colonic lamina propria venules (Streeter et al., 1988; Nakache et al., 
1989). In contrast, CCL25/TECK, the ligand of CCR9, is selectively expressed in the 
small intestine, but not in the colon, with highest expression in the duodenum 
(Stenstad et al., 2007).  
The mechanism of how DCs from Peyer’s patches and mesenteric lymph nodes 
elevate the expression of α4β7 and CCR9 was elucidated by Iwata et al. (Iwata et al., 
2004). They demonstrated that vitamin A-deficient mice have a markedly reduced 
α4β7
+ CD4+ T cells in their spleen, mesenteric lymph nodes and Peyer’s patches. 
They could further show that all-trans-retinoic acid (RA), a vitamin A metabolite, is 
essential for the production of gut-specific α4β7+ T cells (Figure 2.1). In vitro 
incubation of T cells with all-trans-RA in presence of antigenic stimulation 
significantly increases the expression of α4β7. This upregulation is due to the binding 
of RA to its receptor in the T cells, the heterodimer transcription factor RAR/RXR that 
subsequently drives transcriptions of various genes, including α4 integrins (Kastner et 
al., 1995; Mangelsdorf and Evans, 1995; DeNucci et al., 2010). Furthermore, they 
discovered that DCs of Peyer’s patches and mesenteric lymph nodes express not 
only alcohol dehydrogenases, but most importantly, also high levels of retinal 
dehyrogenases (Iwata et al., 2004). Whereas alcohol dehydrogenases convert 
vitamin A or retinol to retinal reversibly, retinal dehyrogenases catalyze the 
irreversible conversion from retinal to RA (Duester, 2000).  
The capability to enhance α4β7 expression on T cells and direct them to the gut is not 
only a feature of the GALT-DCs and the intestinal DCs. It has been recently 
discovered that liver-derived APC, namely the sinusoidal endothelial cells are able to 
induce α4β7 expression on T cells (Neumann et al., 2012). Furthermore, intestinal 
enterocytes are also able to produce RA (Lampen et al., 2000). 
The diverse potential sites for activation give benefits such as mounting a rapid 
immune response in a given area. However, they also bear the risks and potentials to 
develop improper immune reactions leading to autoimmune diseases.  
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Figure 2.1 A model of T cell entry into the Peyer’s patch mediated by interaction of α4β7 with 
MAdCAM-1. Upon stimulation by activated dendritic cells producing retinoic acid, α4β7 
expression is upregulated, which leads to migration of effector T cells into the intestine.  
 
2.2.3 Implication of α4β7 in diseases 
 
As a crucial homing receptor into the gastrointestinal tract, it is well established that 
α4β7 is involved in the incurrence of several diseases such as HIV infection, graft–
versus- host-disease, primary sclerosing cholangitis and inflammatory bowel 
diseases. Studies done by Arthos et al. demonstrate that α4β7+ CD4+ T cells in 
genital mucosa are highly prone to infection by HIV virus due to high binding affinity 
of the viral envelope protein gp120 to α4β7, which consists of a highly conserved 
tripeptide that mimics the tripeptide structure of MAdCAM-1 (Arthos et al., 2008). The 
binding of gp120 to α4β7 initiates the formation of virological synapses that facilitate 
efficient cell-to-cell spreading of the virus, hence massive depletion of CD4+ T cells. 
In an acute graft-versus-hose-disease, a serious and often fatal complication 
following an allogeneic stem cell transplantation, recipient’s tissues such as 
gastrointestinal tract, liver and skin are attacked by donor-derived CTLs. 
HEV
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The donor derived CTLs utilize L-selectin and α4β7 to migrate to mesenteric lymph 
nodes, where they are activated by APCs presenting host antigens. The absence of 
both homing receptors on donor T cells has been shown to markedly ameliorate the 
acute colitis caused by the graft-versus-hose-disease due to significant reduction in 
early donor T-cell homing into the mesenteric lymph nodes (Dutt et al., 2005; 
Waldman et al., 2006).  
The role of α4β7 in inflammatory bowel diseases has also been exploited. 
Inflammatory bowel disease is a chronic inflammatory disorder in the gastrointestinal 
tissues that includes Crohn’s disease and ulcerative colitis. One of the hallmarks of 
inflammatory bowel disease is the uncontrolled recruitment of leukocytes into the 
sites of inflammation, where they provoke cytokine-mediated tissue injury (Luster et 
al., 2005; Eksteen et al., 2008). Several studies using animal models of inflammatory 
bowel disease have demonstrated that administering antibodies specific for α4 and 
α4β7, but also for MAdCAM-1, ameliorate disease symptoms (Podolsky et al., 1993; 
Hesterberg et al., 1996; Picarella et al., 1997). However, depending upon which 
inflammatory bowel disease models are used, some studies have been yielded 
contradicting results. Colitis models utilizing CD4+ T cell effector function suggest that 
α4β7 is not required for T lymphocyte localization to the intestine and for the colitis 
pathogenesis. Moreover, the adoptive transfer of β7-deficient T cells delays the onset 
of the disease over 9 weeks, however recipient mice still develope colitis at 25 weeks 
(Sydora et al., 2002).   
Another gastrointestinal disease implicating α4β7+ T cells is the primary sclerosing 
cholangitis. It is a chronic liver disease triggered by progressive inflammation that 
affects the biliary tract causing obliteration of the bile ducts, hence cholestasis 
(Ponsioen, 2012). The occurrence of primary sclerosing cholangitis has been 
associated with inflammatory bowel disease as extraintestinal manifestations (Fausa 
et al., 1991; Olsson et al., 1991). Abberant MAdCAM-1 expression on the liver 
endothelium has been shown to be responsible for uncontrolled recruitment of α4β7+ 
T cells (Grant et al., 2001). 
Whereas aberrant recruitment of α4β7+ T cells can lead to the aforementioned 
diseases, a proper trafficking of α4β7+ T cells to clear infection is also required. 
An infection study using recombinant virus (vesicular stomatitis virus) encoding 
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ovalbumin (OVA) demonstrates the critical role of α4β7 for the migration of activated 
CD8+ T cells into the MLN, PP and intestinal mucosa (Lefrançois et al., 1999). 
Furthermore, a study done by Kelly et al. has shown that the trafficking of α4β7+ CLA+ 
effector T cells to the reproductive tract tissue is crucial during chlamydia trachomatis 
infection (Kelly et al., 2009).   
Dysfunction of the recruitment of α4β7+ T cells has been also pointed out as a major 
problem to treat gastrointestinal tumors. Enarsson et al. demonstrated that in human 
gastric tumors the frequency of α4β7+ T cells was significantly decreased and this 
correlated with the decrease expression of MAdCAM-1 in the blood vessels in the 
tumor (Enarsson et al., 2006). Supporting this finding, a recent study in colorectal 
cancer could also reveal a reduced frequency of α4β7+ CD4+ T cells and decreased 
expression of MAdCAM-1 in the tumor tissues compared to unaffected tissues 
(Svensson et al., 2012). 
These numerous evidences of α4β7 involvement in diseases emphasize the 
substantial importance of a proper control of T cell trafficking into the gastrointestinal 
tract.  
 
2.2.4 Control of gut migration 
 
Whereas the migration of effector T cells to certain peripheral tissues, such as skin or 
gut, has been studied in great detail (Mora et al., 2008), the trafficking pattern of 
naïve T cells during antigen-nonspecific immune (bystander) activation has been 
poorly investigated. Since only about one of 105 naïve T cells receives the chance to 
develop into an effector T cell during activation (Abbas and Janeway, 2000), it would 
be a high risk for the organism not to control the migration of the remaining naïve 
T cells, that are also in an activated but antigen-unspecific state (bystander 
activation) (Bangs et al., 2006). The fact that the gut is the largest peripheral tissue 
with tremendous amount of antigens derived from food and commensal bacteria, 
underlines the importance of possessing a tight surveillance for incoming T cell 
residents into the gut, in order to prevent unnecessary immune response causing 
autoimmune diseases. 
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Studies in our group have shown that upon Salmonella typhimurium but also 
Escherichia coli bacterial infection, the expression of α4β7 on naïve T cells is 
decreased. Moreover, this decrease is also observed when T cells, cultured as 
splenocytes, are incubated with Toll-like receptors (TLR) ligands. The TLRs are 
receptors for conserved bacterial compounds that reside on the cell surface and in 
the endosome (Barton and Kagan, 2009; McGettrick and O’Neill, 2010). Furthermore, 
the downregulation was abrogated when using MyD88-deficient splenocytes. 
MyD88 is a crucial adaptor in TLR signaling (Medzhitov et al., 1998).  
An elegant study in our group using an adoptive transfer model demonstrated that 
upon immune activation by CpG, the TLR9 ligand, and the presence of OVA, an 
antigen model, wild-type T cells in the MLN and PP decreased their α4β7 expression 
leading to their impaired migration into the GALT. In contrast, the OT-I T cells, 
a transgenic CD8+ T cells specific for OVA, increased their α4β7 expression as 
previously described (Heidegger et al., submitted). The increased α4β7 expression on 
OT-I T cells upon presence of TLR ligands and antigen confirmed an existing 
previous study (Johansson-Lindbom et al., 2003). 
Whereas these studies have started to elucidate trafficking pattern of naïve T cells 
during bacterial infection, the migration of naïve T cells during viral infection still 
needs to be clarified.  
 
2.3 Type I interferon signaling 
 
One powerful weapon to fight viral invasion is the secretion of interferons (IFNs), a 
family of structurally related cytokines with antiviral activity, which can be expressed 
by almost every cell type, including leukocytes, fibroblasts and endothelial cells 
(González-Navajas et al., 2012). One of their functions is to trigger activation of 
genes that block viral replication in infected cells and to prevent apoptosis. 
Furthermore, they activate various types of innate and adaptive immune cells such 
as macrophages, NK, DC, B cells and CD8+ T cells, promote neutrophil survival and 
the polarization of effector CD4+ T cells into the Th1 type (Wang and Fish, 2012). 
Th1 cells produce certain cytokines enabling the immune system to clear viral and 
intracellular bacterial infections such as IFN-γ (Mosmann and Coffman, 1989; Zhu 
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and Paul, 2008). Based on their structural and functional properties, IFNs can be 
classified as type I, type II and type III IFNs (Takaoka and Yanai, 2006). As we are 
focusing on type I IFN, the next chapter will describe more specifically its induction, 
signaling and role in diseases and therapeutic settings.  
 
2.3.1 Induction of type I IFNs 
 
In humans and mice, the type I IFN family consists of 16 members including 12 IFN-α 
subtypes, IFN-β, IFN-ε, IFN-ω, IFN-κ (González-Navajas et al., 2012). 
The best-studied members are IFN-α and IFN-β.   
The induction of type I IFN is initiated by recognition of microbe-specific pathogen-
associated molecular patterns (PAMPS) by some members of the TLR family on the 
cell surface and in endosomes such as TLR3, TLR4, TLR7 and TLR9. These TLRs 
detect dsRNA, lipopolysaccharide (LPS), ssRNA and bacterial unmethylated 
CpG-containing dsDNA, respectively (Takeda et al., 2003; Heil et al., 2004) (Figure 
2.2). Upon recognition of foreign nucleic acids in the endosome, TLR7 or TLR9 
recruits the adaptor myeloid differentiation primary-response protein 88 (MyD88). 
After a sequential recruitment process of other proteins, the signaling leads to the 
activation of among others the transcription factors NF-κB and AP1 which initiate the 
transcription of numerous proinflammatory cytokines, but also of type I IFN (Monroe 
et al., 2010; Desmet and Ishii, 2012).  
In contrast, the activation of TLR3 in the endosome engages another adaptor protein 
termed TRIF (TIR-domain-containing adaptor protein) inducing mainly the 
transcription of type I IFN. TLR4 is among TLRs unique since it is compatible to both 
adaptors (Yamamoto et al., 2003). Whereas type I IFN induction by TLR3 and TLR4 
via TRIF takes place in broad range of cell types, TLR7- or TLR9- mediated type I 
IFN secretion occurs mainly in DCs, particulary plasmacytoid DC (González-Navajas 
et al., 2012).  
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Figure 2.2: A simplified model of TLR and RIG-I-like-receptors (RLRs) signaling. Figure was 
modified from Yoneyama and Fujita (2010), Kawai and Akira (2010). 
 
Another safeguard mechanism for viral offence that has evaded the TLR recognition 
is provided by the cytosolic sensors retinoic-acid-inducible gene I (RIG-I) and 
melanoma differentiation-associated gene 5 (MDA-5) that are capable of identifying 
viral RNA (Barral et al., 2009). Additionally, other receptors such as the stimulator of 
IFN-genes (STING), an endoplasmic reticulum-associated protein, and DAI (DNA-
dependent activator of IRFs) have also been described to induce type I IFNs in 
response to cytosolic DNA (Takaoka et al., 2007; Ishikawa and Barber, 2008). Like 
TLR signaling, detection of foreign nucleic acids in the cytosol by RIG-I and MDA-5 
elicits signaling cascades activating the transcription factors NF-κB and IRF3 and 
IRF7 mediated by the adaptor mitochondrial antiviral signaling protein (MAVS) on the 
mitochondrias (Yoneyama and Fujita, 2007).  
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2.3.2 Signaling pathways activated by type I IFNs 
 
After the initiation of type I IFN induction induced by PAMPs recognition, secreted 
proinflammatory cytokines and type I IFN, mainly IFN-α and IFN-β, provoke a 
secondary signaling cascade by binding to their receptors (Figure 2.3).  Recognition 
of IFN-α and IFN-β is conveyed by the cognate IFN receptor complex, IFNAR1 and 
IFNAR2 (Novick et al., 1994; Uzé et al., 2007). IFNAR1 and IFNAR2 are associated 
with the Janus protein tyrosine kinases (Jak PTKs), Tyk2 and Jak1, respectively. The 
binding of both types of IFNs leads to cross-activation of these JAK PTKs leading to 
specific tyrosine phosphorylation of their target substrates, Stat1 and Stat2 (“signal 
transducer and activators of transcription”) (Darnell et al., 1994; Ihle and Kerr, 1995; 
Schindler and Darnell, 1995; Stark et al., 1998). Subsequently, the phosphorylation 
allows these two Stats to form a transcription factor with the DNA-binding subunit 
IRF-9 termed IFN-stimulated gene factor 3 (ISGF3) (Darnell et al., 1994; Haque and 
Williams, 1994; Bluyssen et al., 1996). Finally, the complex ISGF3 then translocates 
into the nucleus and initiates the transcription of numerous IFN-stimulated genes 
(ISGs) by binding to the IFN-stimulated response elements (ISREs) at the promoter 
site (Qureshi et al., 1995). The ISGs are responsible for the antiviral and 
immunomodulatory properties of the IFNs. To note, although the above-mentioned 
pathway downstream of IFNAR1/2-complex is the most prominent pathway activated 
by type I IFN, there are other type-I-IFN-dependent signaling pathways described 
(Takaoka and Yanai, 2006; González-Navajas et al., 2012).  
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Figure 2.3: A simplified model of type I IFN signaling. Figure was modified from González-
Navajas et al., 2012. 
  
2.3.3 Implication in diseases and therapeutic use of type I IFN 
 
Despite its beneficial effects in commencing the immune response during viral or 
bacterial infection, type I IFN has also been connected to several autoimmune and 
inflammatory disorders such as systemic lupus erythematosus, coeliac disease and 
psoriasis.  
Systemic lupus erythematosus is a systemic autoimmune disease in which 
autoreactive T cells assault the body’s own cells and tissues leading to inflammation 
and tissue damage. It has been shown that systemic lupus erythematosus patients 
display elevated levels of IFN-α in their blood that is produced mainly by 
plasmacytoid DCs (Ytterberg and Schnitzer, 1982; Bengtsson et al., 2000; 
Rönnblom, 2011). Similar to systemic lupus erythematosus, coeliac disease and 
psoriasis affecting the small intestine and skin respectively, are caused by 
uncontrolled overproduction of type I IFN (Funk et al., 1991; Schmid et al., 1994; 
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Monteleone et al., 2001). Nonetheless, type I IFN has also been used to treat 
diseases such as multiple sclerosis (an inflammatory disease affecting the brain), 
inflammatory bowel diseases and cancer (Ann Marrie and Rudick, 2006; Ferrantini et 
al., 2007; Musch et al., 2007). 
 
2.4 Adoptive T cell therapy 
 
As it has been mentioned in chapter 2.2, the trafficking into peripheral tissue is an 
essential step for cytotoxic CD8+ T cells (CTL) to actuate their function in the tissue, 
i.e. to eliminate virus-infected cells by inducing programmed cell death apoptosis 
(Berke, 1995). Furthermore, CTLs are able to recognize and to eradicate tumor cells 
due to the presentation of tumor-antigens on MHC class I, which ideally represent 
parts of mutated proteins in the tumor cells (Cerottini et al., 1992; Boon et al., 1994).  
Adoptive T cell transfer in tumor immunotherapy is based on the fact that CTL can kill 
tumor cells and administering ex vivo expanded T cells into the body can reconstitute 
the immunity, which has been lost in tumor patients due to tumor tolerance (Restifo 
et al., 2012). Numerous studies have demonstrated that infiltration by Th1 cells 
(IFN-γ-producing CD4+ T cells) and CTL into the tumor correlates with tumor 
reduction and prolonged survival of patients (Galon et al., 2006).  
However, in many cases these tumor-infiltrating lymphocytes are paralysed and 
incapable of tumor elimination since the tumor has evolved strategies to overcome 
immune recognition by establishing an immunosuppressive microenvironment. This 
includes the downregulation of MHC or co-stimulatory molecules, secretion of factors 
limiting CTL cytotoxic activity, expression of inhibitory ligands and decrease of 
homing signals for CTLs (Ngo et al., 2011). Circumventing these obstacles is still one 
of the major challenges in the immunotherapy research field. 
Another issue is the restoration of tumor-infiltrating lymphocytes function. Although it 
has been shown that tumor-infiltrating lymphocytes outside the tumor 
microenvironment can exert their specific functions, some studies have also shown 
that most of the tumor-specific T cells have low-affinity TCRs to the tumor antigens. 
This is due to the fact that tumor antigens are mostly self-antigens and therefore 
T cells recognizing these antigens are negative selected during maturation. 
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Enhancing the TCR affinity to tumor antigens by introducing transgenic TCRs using 
integrating retroviral, lentiviral or plasmids is therefore one of strategies to improve 
clinical outcome (Park et al., 2011).  
A further drawback is the blockade of T cells to enter the tumor due to the obstruction 
of homing signals. In our study, we could show that administering T cells from 
immunized mice can induce efficient eradication of subcutaneous gastric tumors in 
mice. However, in the same mice T cells are retained in the periphery of an 
autochtonous gastric tumor. This retention can also be seen in other studies (Galon 
et al., 2006; Mrass et al., 2006; Boissonnas et al., 2007). The enhanced expression 
of a homing signal such as MAdCAM-1 and the generation of tumor-antigen-specific 
CTLs with increased homing receptor α4β7 might therefore be a promising strategy to 
direct T cells into the gastrointestinal tumors.  
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3 Materials and Methods 
3.1 Materials 
3.1.1 Technical equipment 
Alpha Imager (gel documentation) Alpha Innotech, San Leandro, USA 
Balance (LP 6209)  Sartorius, Göttingen, Germany 
BD FACS Canto II BD Biosciences, San Diego, USA 
Cell culture CO2 incubator (BD 6220)  Heraeus, Hanau, Germany 
Cell culture laminar flow Heraeus, Hanau, Germany 
Cell strainer (40 and 70 µm, nylon mesh)  Fisher Scientific, Leicestershire, UK 
Centrifuge 5424 Eppendorf, Hamburg, Germany 
Centrifuge 5417R  Eppendorf, Hampburg, Germany 
DynaMag 15/50 magnet Invitrogen Dynal, Carlsbad, USA 
Fluo-link (UV irradiation)  Vilber Lourmat, Marne La Vallée, 
France 
Gel electrophoresis system   Bio-rad, Munich, Germany 
MACSQuant Analyzer Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Microscope Axiovert 25  Zeiss, Jena, Germany 
Mithras LB940 multilabel plate reader Berthold, Bad Wildbach, Germany 
Multifuge 3L-R Heraeus, Hanau, Germany 
Nanodrop ND-1000   NanoDrop, Wilmington, USA 
Neubauer hemocytometer Optik Labor Frischknecht, Balgach, 
Germany 
pH meter 3505 Jenway, Staffordshire, UK 
Power Supply 200/2.0 Biorad, Munich, Germany 
Refrigerators (4°C, -20°C, -80°) Thermo scientific, Waltham, USA 
Thermocycler T3  Biometra, Göttingen, Germany 
Thermomixer  Eppendorf, Hamburg, Germany 
IKA® Vortex 3 IKA, Staufen, Germany 
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3.1.2 Chemical, reagents and buffer 
Acetic acid Fisher Chemical, Leicestershire, UK 
Ampicillin  Fisher Scientific, Leicestershire, UK 
Agarose LE Biozym, Hess. Oldendorf, Germany 
Aqua ad injectabilia  Braun Melsungen AG, Melsungen, 
Germany 
BD FACS lysing solution (10x) BD Biosciences, San Diego, USA 
BD Pharm Lyse (10x) BD Biosciences, San Diego, USA 
Bovine serum albumine (BSA)  Sigma Aldrich, Steinheim, Germany 
Bromophenol blue, sodium salt Promega, Wisconsin, USA 
Calcium chloride   Acros Organics, Geel, Belgium 
Dimethyl sulfoxide (DMSO) Sigma Aldrich, Steinheim, Germany 
Dulbecco’s PBS (1x) PAA, Pasching, Germany 
Ethanol Amresco, Solon, USA 
Ethidium bromide Sigma Aldrich, Steinheim, Germany 
Ethylendiaminetetraacetic acid (EDTA) Sigma Aldrich, Steinheim, Germany 
FACSFlow, FACSSafe Becton Dickinson, Heidelberg, Germany 
Glycerol Fisher Chemical, Leicestershire, UK 
Isofluorane (Forene®) Abbott, Zug, Switzerland 
Isopropanol (70 Vol%) Apotheke Innenstadt, LMU Munich 
LB broth (Lennox)  Condalab, Madrid, Spain 
LB agar (Lennox) Condalab, Madrid, Spain 
2-Mercaptoethanol Acros Organics, Geel, Belgium 
PharmLyse (10x) RBC lysis  Becton Dickinson, Heidelberg, Germany 
Potassium chloride Fisher Chemical, Leicestershire, UK 
Saponin Serva Electrophoresis GmbH, 
Heidelberg, Germany 
Sodium carbonate Sigma Aldrich, Steinheim, Germany 
Sodium chloride Sigma Aldrich, Steinheim, Germany 
Sodium hydrogenphosphate Fisher Chemical, Leicestershire, UK 
Sodium phosphate Sigma Aldrich, Steinheim, Germany 
Sulfuric acid (H2SO4, 2N)  Apotheke Innenstadt, LMU Munich 
TMB Substrate Reagent Set Becton Dickinson, Heidelberg, Germany 
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Tris(hydroxymethyl)amino methane 
Biosolve BV, Valkenswaard, 
Netherlands 
Tween 20  Fisher Scientific, Leicestershire, UK 
 
 
Buffer 1 (for T cell isolation)  
1x PBS (without Ca2+ and Mg2+) 
0.1% BSA 
2 mM EDTA 
pH 7.4 
 
 
2% BSA 
Dissolve 1 g BSA in 50 ml sterile water 
Sterile filtrate with 0.2 µm filter 
 
Buffer to wash Dynabeads® mouse T 
cell activator 
1x PBS 
0.1 % BSA 
2 mM EDTA 
pH 7.4 
 
Blasticidin (5 mg/ml) 
Dissolve 50 mg Blasticidin in 10 ml 
sterile PBS, aliquot to 1 ml, freeze at -
20°C 
ELISA coating buffer 1 
0.2 M Sodium phosphate  
in water  
pH 6.5  
 
ELISA coating buffer 2 
0.1 mM Sodium carbonate 
in water 
pH 9.5 
 
ELISA assay diluent  
10% FCS  
in PBS 
pH 7.0 
 
ELISA wash buffer  
0.05% Tween  
in PBS 
6x loading dye 
0.05 mg Bromophenol blue 
2.8 ml ddH2O 
6 ml Glycerin 
 
20X Saponin 
20% (w/v) saponin in 1x PBS 
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50x TAE 
to 900 ml ddH2O 
242.3 g Tris base 
57 ml Acetic acid 
18.6 g EDTA 
Fill to 1 L  
Transfection buffer 
1.6 g NaCl 
74 mg KCl 
50 mg Na2HPO4 
1 g HEPES 
add 100 ml ddH2O, pH 6.76 
 
CaCl2 2M 
Dissolve 11 g CaCl2 in 50 ml sterile 
ddH2O 
Sterile filtrate with 0.2 µm filter 
 
Puromycin (10 mg/ml) 
Dissolve 100 mg with 10 ml sterile PBS  
Aliquot 50 µl, store at -20°C 
 
3.1.3 Kits 
Cell Proliferation Dye eFluor® 670 eBiosciences, San Diego, USA 
Cell Trace CFSE cell proliferation kit  Invitrogen/Molecular Probes, Eugene, 
USA 
Dynal® Mouse T cell negative isolation 
Kit  
Invitrogen/Molecular Probes, Eugene, 
USA 
JETSTAR Plasmid purification MAXI kit  Genomed, Florida, USA 
AxyPrep™ plasmid miniprep kit  Axygen biosciences, California, USA 
Wizard® SV Gel and PCR Clean-Up 
System 
Promega, Wisconsin, USA 
 
Cytokine ELISA sets 
IL-6 murine   BD Biosciences, San Diego, USA 
 
Cytokine ELISA antibodies 
Detection of murine IFN-α: 
Capture Ab: Anti IFN-α (RMMA-1)  PBL, New Brunswick, USA 
Detection Ab: Anti IFN-α (polyclonal,   PBL, New Brunswick, USA 
rabbit anti mouse) 
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HRP-conjugated F(ab’)2 fragments  Biomeda, Foster city, USA 
(donkey anti rabbit) 
3.1.4 Cell culture reagents and media 
Blasticidin PAA, Pasching, Austria 
Chloroquine LabForce, Nunningen, Switzerland 
β-Mercaptoethanol  Sigma Aldrich, Steinheim, Germany 
Dulbecco’s modified Eagle’s medium 
(DMEM), high glucose 
PAA, Pasching, Austria 
Fetal calf serum (FCS) GibcoBRL (invitrogen), Karlsruhe, 
Germany 
L-Glutamine 200 mM PAA, Pasching, Austria 
HEPES PAA, Pasching, Austria 
MEM-NEAA (non-essential amino acids) GibcoBRL (Invitrogen), Karlsruhe, 
Germany 
Phosphate buffered saline (PBS) PAA, Pasching, Austria 
Penicillin/Streptomycin (100x) PAA, Pasching, Austria 
Protamine sulfate Merck, New Jersey, USA 
Puromycin PAA, Pasching, Austria 
Retronectin Takara, Shiga, Japan 
Roswell Park Memorial Institute (RPMI) 
1640 medium 
PAA, Pasching, Austria 
Sodium pyruvate PAA, Pasching, Austria 
Trypan Blue solution Eurobio, Cortaboeuf, France 
Trypsin EDTA (1x) PAA, Pasching, Austria 
VLE RPMI 1640 medium (very low 
endotoxon) 
Biochrom, Berlin, Germany 
   
T cell medium 
RPMI 1640 
10% FCS 
1% L-Glutamine 
1mM HEPES 
Plat-E medium 
DMEM high glucose 
10% FCS 
1% Glutamine 
100 IU Penicillin, Streptomycin 
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1 mM Sodium Pyruvate 
100 IU/ml penicillin, streptomycin 
50 µM 2-mercaptoethanol 
 
10 µg/ml Blasticidin 
1 µg/ml Puromycin 
 
Plat-E hunger medium  
DMEM high glucose 
3% FCS 
1% Glutamine 
100 IU Penicillin, Streptomycin 
10 µg/ml Blasticidin 
1µg/ml Puromycin 
 
Freezing medium for Plat-E and RF33 
cells 
500 µl 100% FCS 
40 µl DMSO  
Mix well 
Add to 5 millions cells/ 400 µl in a cryo 
tubes 
Freeze immediately to -80°C 
 
Cytokines and growth factors: 
LEAF™ Purified anti-mouse CD3ε 
Antibody (clone: 145-2C11) 
Biolegend, San Diego, USA 
LEAF™ Purified anti-mouse CD28 
Antibody (clone: 37.51) 
Biolegend, San Diego, USA 
Dynabeads® Mouse T-Activator 
CD3⁄CD28 for Cell Expansion and 
Activation 
Invitrogen, Eugene, USA 
IFN-α, mouse, recombinant Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Poly I:C Invitrogen/Molecular Probes, Eugene, 
USA 
CpG 1826 (CpG) 
(5’-TCCATGACGTTCCTGACGTT-3’) 
Coley Pharmaceuticals, Langenfeld, 
Germany 
Recombinant murine IL-2  Peprotech, Rocky Hill, USA 
Recombinant mouse IL-15 (carrier-free) Biolegend, San Diego, USA 
Resiquimod (R848) Alexis Biochemicals, Lausen, 
Switzerland 
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Blocking antibodies: 
Description Isotype Clone Distributor 
LEAF™ purified anti-mouse IL-6 
antibody 
Rat IgG1, κ MP5-20F3 BioLegend 
LEAF™ purified anti-mouse 
IFNAR-1 antibody 
Mouse IgG1, κ  MAR1-5A3 BioLegend 
 
Viruses: 
The encephalomyocarditis virus (EMCV), vesicular stomatitis virus (VSV) and a 
mutant form of VSV as well as Sendai virus were kindly provided from the group of 
Prof. Simon Rothenfußer, Division of Clinical Pharmacology, University of Munich. 
 
3.1.5 FACS antibodies 
Description Isotype Clone Distributor 
anti-CD3 Armenian Hamster 
IgG 
145-2C11 BioLegend 
anti-CD4 Rat IgG2a, κ  RM4-5 BioLegend 
anti-CD8a Rat IgG2a, κ  52.67 BioLegend 
anti-CD45R/B220 Rat IgG2a, κ  RA3-6B2 BioLegend 
anti-CD69 Armenian Hamster 
IgG  
HI-2F3 BioLegend 
anti-LPAM-1 (α4β7) Rat IgG2a, κ  DATK32 BioLegend 
anti-CD29 Armenian Hamster 
IgG  
HMß1-1 BioLegend 
anti-CD49d Rat IgG2b, κ  R1-2 BioLegend 
anti-β7 Rat IgG2a, κ  FIB504 BioLegend 
anti-LFA1 Rat IgG1, κ  H155-78 BioLegend 
anti-CCR7 Rat IgG2a, κ  4B12 BioLegend 
anti-CCR9 Rat IgG2b 242503 R&D Systems 
anti-CD62L Rat IgG2a, κ  MEL-14 BioLegend 
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anti-CD44 Rat IgG2b, κ  IM7 BioLegend 
anti-CD31 Rat IgG2a, κ  MEC13.3 BioLegend 
FITC Armenian 
Hamster IgG 
Isotype Ctrl 
Antibody 
Armenian Hamster 
IgG  
HTK88 BioLegend 
FITC Rat IgG2b, κ 
Isotype Ctrl 
Antibody 
Rat IgG2b, κ  MRG2b-85 BioLegend 
FITC Rat IgG2a, κ 
Isotype Ctrl 
Antibody 
Rat IgG2a, κ  RTK2758 BioLegend 
 
Plastic materials for cell culture experiments were purchased from Becton Dickinson 
(Heidelberg Germany), Brunschwig (Basel, Switzerland), Corning (Corning, USA), 
Eppendorf (Hamburg, Germany),  Fisher Scientific (Leicestershire, UK) and Sarstedt 
(Nümbrecht, Germany). 
 
3.1.6 Molecular biology 
Templates for PCR: 
cDNAs Clone ID Catalog number Company 
ITGA4 30093248 MMM1013-98478859 Thermo Scientific, Leicestershire, UK 
ITGB1 5721348 MMM1013-9497715 Thermo Scientific, Leicestershire, UK 
ITGB7 4187781 MMM1013-65317 Thermo Scientific, Leicestershire, UK 
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Primers for PCR: 
Primers were ordered from Eurofins MWG Operon (Ebersberg, Germany) with 
following sequences: 
 
Name of primer Sequence (5’ – 3’) 
ITGA4 forward ATAAGAATGCGGCCGCATGGCTGCGGAACG 
ITGA4 reverse CCGGAATTCTCAGTCATCATTGCTTTTGC 
ITGB1 forward ATAAGAATGCGGCCGCATGAATTTGCAACTGGTTTCCTGG  
ITGB1 reverse CCGGAATTCCCCTCATACTTCGGATTGACCAC 
ITGB7 forward ATAAGAATGCGGCCGCATGGTGGATTCATCAACTGTTCTC 
ITGB7 reverse CCGGAATTCTCAGTCTGCTTCCCTGGTCAGAG 
Table 2. Sequence of primers used for amplification of the genes ITGA4 (integrin α4), ITGB7 
(integrin β7), ITGB1 (integrin β1). Sequences marked with green or red indicate the restriction 
site of NotI and EcoRI, respectively. 
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Primers for sequencing: 
Primers were ordered from Eurofins MWG Operon (Ebersberg, Germany) with 
following sequences: 
Name of primer Sequence (5’ – 3’) 
ITGA4 primer 1 GCTTTTCCTATCTGTTCGTG 
ITGA4 primer 2 GGCTACTCAGTTGGAGCTGGAC 
ITGA4 primer 3 TGTGTTTCTCATATAAAGGC 
ITGA4 primer 4 GACCAAGTGAGGGACAACAG 
ITGB1 primer 1 CCACCAAGTTTCCCATCTCCA 
ITGB1 primer 2 AAGGTGGCTTTGATGCAATC 
ITGB1 primer 3 AGACATGGACGCTTACTGCAG 
ITGB7 primer 1 GTTCCTGGCAGAGGGCAGCC 
ITGB7 primer 2 TTTCACCACGTGCTGTCCCTCAC 
ITGB7 primer 3 AGTGATGGACAGGGGGACCTTC  
ITGB7 primer 4 GCTGCAGGAGGTCACACATTCTGTGC 
Table 3. Sequence of primers for sequencing 
 
Vector: 
The retroviral vector pMP71 was kindly provided by Prof. Dr. Baum, Department of 
Experimental Haematology, Medizinische Hochschule Hannover.  
Reagents and cells for cloning: 
Pfu DNA Polymerase (native) Fermentas, St. Leon-Rot, Germany 
T4 DNA Ligase  Fermentas, St. Leon-Rot, Germany 
NotI  Fermentas, St. Leon-Rot, Germany 
Buffer O (orange) Fermentas, St. Leon-Rot, Germany 
EcoRI Fermentas, St. Leon-Rot, Germany 
GeneRuler™ 1kb DNA Ladder Fermentas, St. Leon-Rot, Germany 
1 Kb Ldder DNA Marker  Axygen Biosciences, California, USA 
Max Efficiency DH5a Competent Cells 
 
Invitrogen, Eugene, USA 
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3.1.7 Software 
Adobe Illustrator CS4 Adobe System, San Jose, USA 
Adobe Photoshop CS4 Adobe System, San Jose, USA 
FlowJo Tree Star, Ashland, USA 
GraphPad Prism5 Software  GraphPad Software inc., La Jolla, USA 
Lasergene® SeqMan Pro™ DNASTAR Inc., Wisconsin, USA  
Microsoft Office Microsoft, Redmond, USA 
NCBI Entrez Gene www.ncbi.nlm.nih.gov/sites/entrez?db=gene 
Zotero Roy Rosenzweig Center, Virginia, USA 
 
3.2 Cell culture 
3.2.1 General cell culture and cell viability testing 
All cells were cultured in tissue culture flasks at 37°C, 5% CO2 and 95% humidity. All 
manipulations were conducted in a sterile condition under laminar flow hood. To 
check cell viability and determine cell concentration Trypan blue staining was used. 
Live cells are excluded from staining with Trypan blue, since it is not able to cross 
into live cells with intact cell membrane. However, it can traverse into dead cells. 
Thus, dead cells can be observed as blue-colored cells under the microscope. Cell 
suspensions were mixed well in a 0.25% Trypan blue in PBS at appropriate dilution 
(generally at a ratio of 1:10 or 1:20) and subsequently counted in a Neubauer 
hemocytometer under microscope. The cell concentration is calculated as followed: 
Cell concentration (cells/ml) = number of cells counted x dilution factor x 104 
 
3.2.2 In vitro stimulation  
3.2.2.1 With TLR ligands  
In a 96-well plate, splenocytes and T cells (4. 105 – 5. 105 cells/well) were stimulated 
with CpG (5 µg/ml), poly I:C (200 µg/ml), R848 (0.1 µg/ml) for 24 h prior flow 
cytometry analysis.  
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3.2.2.2 With recombinant mouse IFN-α  
In a 96-well plate, splenocytes and T cells (4. 105 – 5. 105 cells/well) were stimulated 
with recombinant mouse IFN-α (103 U/ml) for 24 h prior to FACS analysis. 
 
3.2.2.3 With interleukins 
In a 96-well plate, splenocytes and T cells (4. 105 – 5. 105 cells/well) were stimulated 
with a mixture of interleukins IL-6 (100 ng/ml), IL-1β (100 ng/ml) and IL-12 (100 
ng/ml) in presence or absence of IFN-α (103 U/ml) for 24 h prior to FACS analysis.  
 
3.2.2.4 With viruses 
In a 96-well plate, splenocytes and T cells (4. 105 – 5. 105 cells/well) were incubated 
with EMCV virus (107 pfu/ml), Sendai virus (100 or 250 U/ml), VSV virus (107 pfu/ml) 
and VSVmut virus (107 pfu/ml) for 3 h in a FCS-free T cell medium. Afterwards, cells 
were centrifuged and the supernatants were discarded and replaced with 
FCS-containing T cell medium. After 24 h of incubation, cells were analyzed by flow 
cytometry. 
 
3.2.3 T cell purification 
To purify T cells from splenocytes, a Dynal mouse T cell negative isolation kit from 
Invitrogen was used. The principle of the purification kit is as following: splenocytes 
are incubated with a mixture of monoclonal antibodies against non-T-cell markers 
such as antigens present on B cells, monocytes/macrophages, erythrocytes, 
granulocytes, dendritic cells, NK cells. Dynabeads, which are uniform, 
superparamagnetic polystyrene beads coated with polyclonal sheep-anti rat IgG 
antibody, are added to the suspension and are ideally attached to the mixture 
antibodies that have bound their target cells. The bead-bound cells are separated by 
a magnet from the T cells in the solution. Figure 3.1 depicts an example of 
percentage of T cells obtained after purification. 
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Figure 3.1: Comparison of percentage of T cells before and after purification. Splenocytes were 
stained for B220+, a marker for B cells and CD3+ before purification (left panel) and after 
purification (right panel).  
 
3.2.4 Blocking antibodies 
Splenocytes (4. 105 cells/well) were cultured in a 96-well plate in FCS-free T cell 
medium with CpG (5 µg/ml), EMCV (107 pfu/ml) or Sendai virus (100 U/ml) for 3 h. 
Triplicates were done for each of the groups. Afterwards, cells were centrifuged at 
400g for 7 min to wash out CpG and the virus. The supernatants were discarded and 
FCS-containing T cell medium (200 µl) was added to the cells. After 24 h, cells were 
pelleted by centrifugation (400g, 7 min). The supernatants were pipetted into a new 
96-well plate and cells were checked by flow cytometry for CD3, CD8 and α4β7 to 
assure downregulation of α4β7 expression on CD3+CD8+ cells. The remaining viruses 
in the supernatants were inactivated by UV-light (3 J/m2). The supernatants were 
then added to purified T cells (250.000 cells/well, triplicates for each group). 
Additionally, to each group either no antibodies or antibodies against mouse-anti IL-6 
(5 µg/ml), mouse-anti IFNAR-1 (1.5 µg/ml) or both were added to the wells. Cells 
were incubated overnight (24 h) prior to flow cytometry analysis.  
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3.2.5 Transfection  
The retroviral packaging cell line Platinum-E (Plat-E) was kindly provided by 
Prof. Wolfgang Uckert, Max-Delbrück Center for Medical Medicine. Plat-E cells have 
been shown to induce high titers of retroviruses (Morita et al., 2000).  
Briefly, 8x105 – 1x 106 Plat-E cells in 3 ml culture medium were transferred into a 
tissue-culture treated 6-well plate to yield 60-70% in the next day. On second day, 
the adherent Plat-E cells were incubated with 3 ml hunger medium (with 3% FCS) for 
one hour prior to transfection. This step is important to reduce the amount of serum 
proteins which could lead to increased particle size due to aggregation, thus 
minimizing transfection efficiency (Welzel et al., 2004).  
150 µl Calcium chloride solution containing the vector was prepared as followed: 
Reagents End concentration Volume (Vend=300 µl*) 
100 mM 
Chloroquine 
126.7 µM 0.38 µl 
2M CaCl2 100 mM 15 µl 
Plasmid DNA 18 µg 18 µg or more 
Sterile ddH2O  add to 150 µl 
Table 4. Preparation of calcium chloride solution. * The amount of reagents in µ l (last column) 
was calculated for 300 µ l calcium phosphate transfection solution (Vend=150 µ l calcium 
chloride solution + 150 µ l transfection buffer. 
 
Subsequently, the solution was added drop-wise to the 150 µl transfection buffer (in a 
polystyrene tube) while vortexing the tube constantly. After incubation for 30 min at 
RT, visible precipitation (DNA-calcium phosphate complex) could be observed. The 
300 µl precipitate-containing DNA solution was added slowly (drop-wise) to the 
Plat-E cells and incubated for six hours in the incubator (37°C, 5% CO2) to allow 
uptake of DNA-calcium-phosphate complex. Thereafter, the medium was exchanged 
with 3 ml normal Plat-E medium (with 10% FCS) and cells were cultured for 48 hours 
in a incubator (37°C, 5% CO2).  
The calcium phosphate precipitation method was firstly described in 1973 (Graham 
and Van der Eb, 1973). Interaction of calcium cations with the negatively-charged 
phosphate backbone of the DNA and addition of phosphate-buffered solutions lead to 
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formation of precipitation that can be taken up by the cells via endocytosis. Addition 
of chloroquine can lead to enhanced transfection efficiency by inhibiting the 
acidification of the lysosomes, hence preventing the degradation of transfecting DNA 
by lysosomal hydrolases (Luthman and Magnusson, 1983). Thereafter, the 
transfecting DNA may be incorporated into the genome. However, the mechanism is 
not completely understood. 
 
3.2.6 Transduction of the T-cell line RF33.70 
Transduction of the T cell line RF33.70 was performed as following. A 24-well plate 
was incubated with 400 µl (12.5 µg/ml) RetroNectin for 2 h at RT. RetroNectin is a 
recombinant human fibronectin fragment with three functional domains that are able 
to interact with integrin on target cells and the virus particles. After incubation, the 
plate was blocked with 2% BSA for 30 min at 37°C, before washed once with 2 ml 
1x PBS 25 mM HEPES. Thereafter, 105 cells (in 1 ml) of RF33.70 cell line and 1 ml 
filtered viral supernatant of Plat-E cells (through 0.45 µm filter) together with 4 µg/ml 
protamine sulfate and 1 % HEPES were added to each well and the plate was 
centrifuged at 32°C for 1.5 hours prior to incubation overnight at 37°C, 5% CO2. One 
day after, cells were pelleted, replated with 3 ml medium on a 6-well plate and 
incubated for 3 days. On the 8th day of experiment, transduction efficiency was 
analyzed via FACS.  
 
3.2.7 Transduction of primary T cell line 
 
Transduction of primary T cells was done similarly to RF33.70 cell line. One day prior 
to transduction, spleen was isolated and single cell suspension was performed as 
described in 3.4.3.1. 2x 106 cells/ml were stimulated with 10 IU/ml recombinant IL-2, 
1 µg/ml anti-mouse CD3 and 0.1 µg/ml anti-mouse CD28 overnight in a 6-well plate 
(4 ml/well).  
On the transduction day, a 24-well plate was incubated with 400 µl (12.5 µg/ml) 
RetroNectin for 2 h at RT. After incubation, the plate was blocked with 2% BSA for 
30 min at 37°C, before washed once with 2 ml 1x PBS 25 mM HEPES. Filtered viral 
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supernatant (1 ml) was added to the well and centrifuged at 2700 g, 4°C for 1.5 h. 
Thereafter, viral supernatant was discarded and 1x 106 cells (in 1 ml medium 
containing 10 IU/ml IL-2 and 4x105 Dynabeads® mouse T-activator CD3/CD28) were 
added to each well. The plate was centrifuged at 800g, 32°C for 30 min prior to 
incubation overnight at 37°C, 5% CO2. One day after, cells were again transduced 
with 1 ml filtered viral supernatant per well at 800g, 90 min, 32°C. After 6 hours 
incubation at 37°C, 5°C CO2, 1 ml of supernatant was replaced with 1 ml fresh 
medium (+ 10 IU/ml IL-2). 
One day after, cells were pelleted, replated with 2 ml medium containing 50 ng/ml 
recombinant IL-15 (1x 106 cells/ml) on a 12-well plate and incubated for two days. 
On the 8th day of experiment, transduction efficiency was analyzed via FACS.  
 
3.3 Immunological methods 
3.3.1 Enzyme-linked immunosorbent assay (ELISA) 
Enzyme-linked immunosorbent assay (ELISA) is an antibody-based method to detect 
antigen in a sample. To detect cytokines one can utilize the so-called 
sandwich ELISA where two antibodies recognize the same antigen but two different 
epitopes. The method functions as following: the first antibody (capture antibody) is 
immobilized on a plate surface followed by blocking non-specific binding sites on 
surface before adding the samples. To detect the antigen, a biotinylated second 
antibody (detecting antibody) and subsequently a streptavidin-horseradish 
peroxidase conjugate are added to the antigen that is bound to the capture antibody. 
In presence of hydrogen peroxide, an oxidative reaction of the substrate 3,3’,5,5’ – 
tetramethylbenzidine (TMB) catalyzed by the enzyme horseradish peroxidase leads 
to blue color chromogen. This enzymatic reaction can be halted by adding sulfuric 
acid that causes a color change of the blue chromogen into yellow, which can be 
read on a spectrometer at 450 nm.  
 
3.3.1.1 Measurement of IL-6  
For the measurement of IL-6 concentration, samples were diluted 1:10 and the 
detection was performed according to the protocol from BD OptEIA™ (mouse IL-6 
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ELISA set) with some modifications. Briefly, a 96-well plate was coated with 
50 µl/well diluted capture antibody (1:250, in coating buffer pH 9.5) and incubated 
overnight. After three times washing (150-200 µl ELISA wash buffer), unspecific 
binding sites on the plates were blocked with 150 µl/well assay diluent for 1 h at RT. 
After three times washing, 50 µl of the standards (highest was 1000 pg/ml) and 
samples were added into the wells and incubated for 2 h at RT. The plate was then 
washed five times and 50 µl of diluted detection antibody (1:500) and streptavidin-
conjugated horseradish peroxidase (1:250) were added to each well for 1 h at RT. 
Subsequently, the plate was washed five times and 50 µl/well of substrate solution 
(two solutions, mixed in 1:1 ratio) was added to each well and incubated for 30 min at 
RT in the dark. The reaction was stopped by addition of 25 µl of 2N H2SO4. 
All measurements were read at 450 nm with a wavelength correction substraction at 
590 nm.  
 
3.3.1.2 Measurement of IFN-α 
For the detection of IFN-α, plates were coated overnight at 4°C with 50 µl/well 
capture antibody in coating buffer (1 µg/ml). To block unspecific binding sites on the 
plates, plates were blocked with 150 µl/well assay diluent for 3 h at RT. After washing 
the plates for three times undiluted samples and standard (highest standard was 105 
IU/ml) were applied on the plates and incubated at 4°C for overnight. After washing 
steps, 50 µl of detection antibody (625 ng/ml) was added for 3 h at RT. 
Subsequently, after washing the plates ten times, horseradish peroxidase (HRP)-
conjugated F(ab’)2 fragments (15 µg/ml) were added to the well and incubated for 
3 h at RT. Afterwards, 50 µl/well substrate solution was added for approximately 
30 min at RT in the dark. The reaction was halted by adding 25 µl 2N H2SO4. 
All measurements were read at 450 nm with a wavelength correction substraction at 
590 nm.  
 
3.3.2 Flow cytometry 
Flow cytometry, also referred as “fluorescence-activated cell sorting” (FACS), is a 
method commonly used to measure and analyze physical characteristics of a single 
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particles such as cells, microorganisms and DNA. The measured characteristics can 
be the relative size (up to 0.2 to 150 µm), relative granularity or fluorescence intensity 
of a particle. A flow cytometer is built on three main systems: fluidics, optics and 
electronics. The fluidics system performs the transport of the particles in a stream to 
the laser (interrogation point). The optics system consists of 1) a laser, which 
illuminates the particles at the interrogation point and 2) optical filters that direct light 
signals to appropriate detectors. There are two types of light scattering: 1) the 
forward-scattered light (FSC), which is proportional to the size of a particle and 
detected on the axis of the laser beam in the forward direction by a photodiode, and 
2) the side-scattered light (SSC), which reflects the cell granularity or internal 
complexity and is collected at an angle of 90°C by collection lens. It is therefore 
possible for example to distinguish subpopulations of leukocytes. However, to 
distinguish more defined subpopulations (e.g. CD4+ and CD8+ T cells), fluorochrome-
conjugated antibodies are powerful tools that bind to specific antigens (e.g. CD4 and 
CD8) on target cells. The fluorochromes can be excited by laser beams and they 
emit light which then is passed through different selective optical filters (e.g. 
bandpass filter) and detected by different detectors (e.g. photomultiplier tubes, PMT). 
The last system of a flow cytometry is the electronics system. This system is tasked 
to convert light signals into electronic signals that can be processed by a computer.  
In this thesis, experiments related to the revealing of IFN-α effect on CD8+ T cells 
were conducted with BD FACSCanto™ II. The machine is equipped with three 
different lasers (405-, 488-, 633-nm), which can excite different fluorochromes, and 
three detector arrays that detect emitted lights. Experiments related to transfection 
and transduction were perfomed with a MACSQuant Analyzer (MACS Miltenyi 
Biotec) that also possesses three different lasers. 
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Figure 3.2: Lymphocyte gating strategy. Lymphocytes were gated based on their size and 
granularity in FSC-SSC-plot (left panel). In the next plot cells were gated based on their CD3 
and CD8 expression (middle panel). CD3+ CD8+ cells were analyzed for α4β7 expression (right 
panel). The value of median fluorescence intensity (MFI) was utilized to measure the shift in 
fluorescence intensity in the treated cell populations. 
 
3.3.2.1 Analysis of cell surface expression molecules 
To analyze the expression of cell surface antigens, cell suspensions (2x105 – 
2x106/200 µl in 1x PBS) were stained with fluorochrome-conjugated monoclonal 
antibodies (0.5 µl/antibody) against target antigens for 30 min at 4°C. Subsequently, 
the cells were washed by adding 2-3 ml 1x PBS the cells and centrifuged at 400g, 
4°C for 5-7 min. Afterwards, this washing step was conducted one more time prior to 
flow cytometry acquisition. Data analysis was performed utilizing the software 
FlowJo. 
 
3.3.2.2 Analysis of intracellular integrins 
To analyze the percentage of produced integrins in the cytosol, intracellular staining 
was performed as following: 
200 µl of each cultured cells in a well (Plat-E, RF33.70 or primary T cells) were 
transferred to 96-well plate. After centrifugation (2200 rpm, 2 min, RT), medium was 
discarded and cells were gently vortexed. For fixation, cells were incubated with 
100 µl of 1x BD FACS™ lysing solution (diluted in ddH2O) for 8 min at RT. 
Thereafter, cells were washed with 100 µl 1x saponin (diluted in sterile PBS) and 
centrifuged as above. Cells were again washed and permeabilized with 150 µl 
1x saponin. Subsequently, cells were centrifuged before adding 50 µl antibody-mix 
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against α4, β1 and β7 (1:400, diluted in 1x saponin). After 20 min incubation at 4°C, 
cells were washed with 150 µl 1x saponin and centrifuged. Afterwards, cells were 
washed with 150 µl 1x PBS. For measurement, cells were resuspended in 150 µl 
1x PBS. 
The permeabilization of the cell membrane by saponin is due to the reversible 
complexation of saponin with chloresterol in the cell membrane allowing forming of 
pores. It is therefore important to 1) fixate the cells, to avoid leakage of cytosolic 
proteins out of the cells and 2) add saponin to all steps (except the last washing 
steps).  
 
3.3.2.3 CFSE and eFluor® 670 staining 
To track the ex vivo IFN-α-stimulated splenocytes in the mice, we performed a CFSE 
and eFluor® 670 staining. CFSE, or carboxyfluorescein diacetate succinimidyl ester, 
is a molecule that can diffuse passively into cells and is primarly colorless and non-
fluorescent. When intracellular esterases start to cleave the acetate group, the 
molecule becomes highly fluorescent and reactive and binds to intracellular amine. 
This binding is irreversible and causes the stable retaining of the fluorescent 
conjugates. Excess unconjugated products and by-products passively diffuse back 
into the medium. The fact that the fluorescent conjugates can be inherited by 
daughter cells and they can not be transferred to adjacent cells, makes CFSE to a 
powerful method for tracing cell proliferation in vivo. CFSE is excited by a 488-nm 
laser and emit light at 517 nm. Similar to CFSE, the cell proliferation dye eFluor® 670 
(eBioscience) can also be used for tracing cells in vivo. This dye is excited with a 
633-nm laser and its emission peak is at 670 nm.    
5 µl of 5 mM CFSE was diluted with 45 µl 1x PBS to obtain a concentration of 
0.5 mM. Cells (max. 1 x 108 cells) were resuspended in 1 ml 1x PBS and labeled with 
25 µl of 0.5 mM diluted CFSE (end concentration 12.5 µM). The cells were then 
incubated at 37°C (in incubator) for 15 min and washed twice with 49 ml 1x PBS prior 
to injection into mice.  
For the staining with eFluor® 670, cells were resuspended to a concentration of 
20 x 106 /ml. eFluor® 670 (10 µM) was mixed in 1x PBS into the same volume as cell 
suspension and added to the cell suspension (final concentration 5 µM). The cells 
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were then incubated for 10 min at 37°C (in incubator). To stop the reaction, 5 ml of 
1x PBS was added and the cells were incubated for 5 min on ice. PBS was added to 
the cells and the cells were centrifuged at 400g for 7 min. This washing step was 
repeated one more time.  
 
3.4 Animal experimentation 
3.4.1 Animals 
Female C57BL/6 mice (8-12 weeks old) were obtained from Harlan-Winkelmann 
(Borchen, Germany). IFN-I receptor (IFNAR)-deficient mice on C57BL/6 background 
were kindly provided by Dr. Z. Waibler (Paul-Ehrlich Institute, Langen, Germany). 
All mice were anesthetized with isofluorane when transferring splenocytes 
retroorbitally. Animal experiments were approved by the local regulatory agency 
(Regierung von Oberbayern, Munich, Germany).  
 
3.4.2 In vivo stimulation 
3.4.2.1 In vivo stimulation with poly I:C 
To investigate the effect of poly I:C on α4β7 expression in vivo, five mice were 
sequentially injected with 250 µg poly I:C (Invitrogen) 120 h and 48 h prior to organ 
isolation.  
 
3.4.2.2 In vivo stimulation with recombinant mouse IFN-α 
To examine the function of IFN-α in vivo, three mice were injected for three days with 
10 µg recombinant mouse IFN-α (kindly provided by Dr. Martin Schlapschy, from the 
chair of Biological Chemistry at the Technical University of Munich). On the fourth 
day secondary lymphoid organs were isolated.  
 
Materials and methods 
 
43 
3.4.3 Organ preparation 
3.4.3.1 Spleen cell isolation 
Mice were killed by cervical dislocation under anesthesia and the spleens were than 
passed through a 40 µm cell strainer to obtain single cell suspensions. Afterwards, 
cell suspensions were centrifuged for 400g, 7 min and erythrocytes were lysed with 
1 ml 1x red blood lysis buffer for 1-2 minutes. To stop the lysis reaction, cell 
suspensions were diluted with 1x PBS (falcon filled to 50 ml). After centrifugation, 
cells were resuspended in 10 ml 1x PBS, counted with Neubauer hemocytometer 
and either kept on ice or used immediately for cell culture experiments or FACS 
staining.  
 
3.4.3.2 Isolation of peripheral and mesenteric lymph nodes 
Mice were killed by cervical dislocation under anesthesia. Peripheral (inguinal) lymph 
nodes were harvested and passed through a 40 µm cell strainer. After centrifugation 
(400g, 7 min) cells were resuspended in 1x PBS and either kept on ice or 
immediately used for in vitro cell culture experiments. 
 
3.4.3.3 Isolation of mesenteric lymph nodes 
Mice were killed by cervical dislocation under anesthesia. Mesenteric lymph nodes 
were harvested and passed through a 40 µm cell strainer. After centrifugation (400g, 
7 min) remaining erythrocytes were lysed in 1x red blood lysis buffer. To stop the 
reaction, 1x PBS were added to dilute the lysis buffer.  After centrifugation (400g, 
7 min) the cells were resuspended in 1x PBS and either kept on ice or immediately 
used for in vitro cell culture experiments. 
 
3.4.3.4 Isolation of Peyer’s patches 
Mice were killed by cervical dislocation under anesthesia. Peyer’s patches along the 
small intestine were collected and passed through a 40 µm cell strainer. After 
centrifugation (400g, 7 min) cells were resuspended in 1x PBS and either kept on ice 
or immediately used for in vitro cell culture experiments. 
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Homing index =    
3.4.4 Lymphocyte in vivo migration assay 
To assess how the migration of splenocytes is affected by IFN-α treatment, 
splenocytes were incubated for 48 h with IFN-α (103 U/ml). After 48 h, untreated and 
IFN-α-stimulated splenocytes were labeled with eFluor® 670 and CFSE, 
respectively, (section 3.3.2.3) and mixed in a 1:1 ratio (each group 1-1.5 x 107 cells 
/75 µl). 150 µl of the mixed population were injected retro-orbitally into mice under 
anesthesia. An aliquot was saved as input ratio for the homing index. 18-24 h post 
injection, secondary lymphoid organs (spleen, peripheral and mesenteric lymph 
nodes and Peyer’s patches) were harvested and single cell suspensions were 
obtained as described in earlier sections. The percentage of transferred splenocytes 
was examined by flow cytometry and the ratio of IFN-α-stimulated splenocytes 
(CFSE-labeled) to untreated splenocytes (eFluor® 670-labeled) in each organ was 
calculated.  
For the calculation of the homing index, the ratio from each organ was divided by the 
ratio of the inputs:  
          [(IFN-α-stimulated splenocytes)organ / (untreated splenocytes)organ)]   
                              [(IFN-α-stimulated splenocytes)input / (untreated splenocytes)input)] 
 
3.5 Molecular biology 
3.5.1 Primer design 
To amplify the gene of the integrins, primers for the specific gene were designed by 
using following criteria: 
1. For the forward primer, the initial sequence at 5’-end (including bases 
encoding start codon) was selected 
2. The length should be at least 20-22 nucleotides 
3. The 3’-end should terminate with several guanosins (G) or cytidins (C) for 
efficient priming 
4. Addition of restriction site for EcoRI and NotI  
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5. Addition of overhangs on 5’-end specific for EcoRI or NotI to allow efficient cut 
of PCR product. The list of overhangs for specific restriction enzymes can be 
found in New England BioLabs Inc. 
(http://www.neb.com/nebecomm/tech_reference/restriction_enzymes/cleavage
_ olignucleotides_old.asp#.UEC_hFShOOf) 
6. For the reverse primer, last sequence in 3’-end (including bases encoding stop 
codon) was selected and reversed into its complementary sequence by 
utilizing a reverse complement tool: 
http://bioinformatics.org/sms/rev_comp.html. 
 
3.5.2 Polymerase chain reaction 
To amplify the gene, the polymerase chain reaction (PCR) was performed. Briefly, 
template double-stranded DNA is separated using high temperature (denaturation 
step). After DNA melting, two short oligonucleotides (primers) anneal to the the 
specific site at 5’ and 3’ end (annealing step). Subsequently, DNA polymerase can 
elongate the primer sequence. The elongated sequence is complementary to the 
template DNA (elongation step). These steps are repeated several times and an 
exponential amplification of the gene can be achieved. 
 
After proceeding with the PCR at different temperatures to find the optimal condition, 
the following program and reaction mix were chosen to amplify the gene of integrins 
α4, β7and β1: 
 
 
Step Temperature  Time  
1 95°C 2 min 
2 95°C 30 sec 
3 65°C 1 min 
4 72°C 4 min 
5 repeat step 2 to 4 for 35x 
6 72°C 10 min 
7 4°C pause 
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Reagents 1x (50 µ l) 
10x Pfu buffer + MgSO4 5 µl 
dNTPs 2 mM 5 µl 
Primer forward 
(ITGA4/ITGB1/ITGB7) 
(10 pmol/µl) 
2.5 µl 
Primer reverse 
(ITGA4/ITGB1/ITGB7) 
(10 pmol/µl) 
2.5 µl 
Template (cDNAs) ≤ 1 µg 
Pfu polymerase 
(2.5 u/µl) 
0.5 µl 
ddH2O Add to 50 µl 
 
3.5.3 Gelelectrophoresis 
To analyze PCR results, PCR products were loaded on 1% agarose gel. Briefly, 2 g 
agarose were dissolved in 200 ml 1x TAE by boiling for 4-5 min and poured into a 
chamber with addition of 10 µl ethidium bromide (stock concentration: 10 mg/ml). 
To 50 µl PCR product, 8.3 µl 6x loading dye was added and the geleletrophoresis 
was performed for 45 min at 100 volts.  
 
3.5.4 Digestion  
PCR products of the genes were cut and purified with Wizard® SV Gel and PCR 
Clean-Up System (Promega) as decribed an their protocol and eluted in 50 µl ddH2O. 
After DNA measurement (∼ 15-20 ng/µl), PCR products were digested as followed: 
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Digestion mix (50 µ l) for PCR products: 
43 µl PCR product 
5 µl 10x Buffer Orange (O) 
1 µl EcoRI (10 u/µl) 
1 µl NotI (10 u/µl) 
 
The digestion with both enzymes leads to formation of sticky ends. Digestion mixes 
were incubated at 37°C for 2 hours before they were purified again with Wizard® SV 
Gel and PCR Clean-Up System.  
The vector pMP71-GFP was digested with EcoRI and NotI to cut out GFP and 
generate compatible sticky ends for the PCR products.  
Digestion mix (50 µ l) for cutting vector: 
2 µg pMP71-GFP 
2 µl 10x Buffer Orange (O) 
1 µl EcoRI (10 u/µl) 
1 µl NotI (10 u/µl) 
Add ddH2O to 20 µl 
 
After incubation at 37°C for 2 hours, to separate GFP from the digested pMP71 
vector, 1% agarose gel was run as described in chapter 0. To purify the vector, the 
band in the gel corresponding to the size of the digested vector, was cut and purified 
using Wizard® SV Gel and PCR Clean-Up System.  
 
3.5.5 Ligation 
To ligate the digested PCR product of the genes and linearized pMP71 vector, an 
amount-ratio of 1:3 and 1:5 (vector:insert) with consideration of size ratio (in kilo base 
pairs, kbp) was calculated as followed: 
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Calculation for the gene α4: 
1:3 (100 ng vector : 300 ng insert) 
pMP71 size : gene α4 size = ∼6 kbp : 3 kbp = 2 : 1 
Amout of PCR product for gene α4 needed: 300 ng/ 2 = 150 ng 
 
1:5 (100 ng vector : 500 ng insert)   
Amout of PCR product for gene α4 needed: 500 ng/ 2 = 250 ng 
 
Same calculation was done for the ligation of the genes β1 and β7:  
1:3 (100 ng vector : 300 ng insert) 
pMP71 size : gene β1 or β7 size = ∼6 kbp : 2.4 kbp = 2.5 : 1 
Amout of PCR product for gene β1 or β7 needed: 300 ng/ 2.5 = 120 ng 
 
1:5 (100 ng vector : 500 ng insert)   
Amout of PCR product for gene β1 or β7  needed: 500 ng/ 2.5 = 200 ng 
 
Ligation mix (25 µ l):  
Reagents 1:3 1:5 
Insert (PCR products) 150 ng* or 120 ng** 250* ng or 200** ng  
Linearized vector pMP71 100 ng 100 ng 
10x T4 DNA ligase buffer 2.5 µl 2.5 µl 
T4 DNA ligase (5 u/µl) 1 µl 1 µl 
ddH2O  add to 25 µl add to 25 µl 
Table 5: Pipetting scheme for ligation mix. * Amount PCR product needed for ligation of the 
gene α4. ** PCR product needed for ligation of the genes β1 or β7 into the pMP71 vector  
 
Ligation mix was incubated for one hour at RT prior to transformation into heat-shock 
competent E.coli cells.  
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3.5.6 Transformation 
After thawing heat-competent DH5α E.coli cells (Invitrogen) on ice, 10 µl of ligation 
mix were added to the E.coli and incubated for two minutes on ice. Subsequently, 
cells were incubated at 42°C for 1 min (without shaking) before adding 1 ml LB 
medium (without ampicillin) and shaked at 37°C, 650 rpm for one hour. Thereafter, 
cells were centrifuged for 1500 rpm, 2 min. After discarding medium, cells were 
resuspended in remaining medium and plated on LB agar containing ampicillin (stock 
solution 100 mg/ml, diluted 1:1000) for overnight at 37°C. The vector pMP71 
possesses an ampicillin resistance gene, which encodes the ampicillin-degrading 
enzyme beta-lactamase.  
 
3.5.7 Colony PCR 
To check which colonies possess the pMP71 vector containing the integrin genes, 
some colonies were numbered, picked with a tip and plated on new LB agars 
containing ampicillin, which were labeled with same numbers. The same tip was 
dipped in a PCR tube containing the following reaction mix: 
Reagents 1x (30 µ l) 
10x Pfu buffer + MgSO4 3 µl 
dNTPs 2 mM 5 µl 
Primer forward 
(ITGA4/ITGB1/ITGB7) 
(10 pmol/µl) 
2.5 µl 
Primer reverse 
(ITGA4/ITGB1/ITGB7) 
(10 pmol/µl) 
2.5 µl 
Pfu polymerase 
(2.5 u/µl) 
0.5 µl 
ddH2O Add to 30 µl 
 
The same PCR program and analysis of PCR products as in chapter 3.5.2 and 3.5.3 
were utilized.  
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3.5.8 Plasmid purification 
E.coli clones, which were positive for the vector containing the integrin genes in 
colony PCR were grown in 3 ml liquid LB medium with ampicillin (diluted 1:1000, 
stock concentration 100 mg/ml) overnight (not more than 16 hours to prevent 
overcrowding of cells thus cell lysis). For long-term storage of the clones, 150 µl of 
E.coli cell suspension were mixed with 850 µl glycerol and freezed at -80°C. Mini 
plasmid purification was proceeded as described in the protocol of the AxyPrep™ 
plasmid miniprep kit (chapter 3.1.3).  
To obtain a higher quantity of the vector for transfection purpose, maxi plasmid 
purification was done using JETSTAR Plasmid purification MAXI kit (chapter 3.1.3). 
Briefly, 1 ml LB medium with ampicillin with one tip of E.coli from agar plate or 
glycerol stock was cultured for around 6-8 hours. Thereafter, preculture was added 
into 500 ml LB medium with ampicillin (in a 2L Erlenmeyer flask covered with 
aluminium foil). The culture was incubated at 37°C, 180 rpm for maximum 16 hours 
before proceeding with the plasmid purification.  
3.5.9 Sequencing 
Purified pMP71 vectors containing the integrin genes were sent to sequecing 
(Eurofins MWG Operon, Ebersberg, Germany). For each sequencing primer, 
sequencing mix was done as followed: 
Sequencing mix 
DNA  50 ng/µl 
Sequencing primer  2 pmol/µl 
ddH2O add to 15 µl 
 
3.5.10 Analysis of gene sequence  
After obtaining the sequencing results from Eurofins MWG Operon, analysis was 
perfomed using the software Lasergene® SeqMan Pro™ to verify compliance of the 
sequence with the cDNA sequence of the integrins obtained in the PubMed 
database. Alternatively, DNA sequence was translated into protein sequence 
(http://web.expasy.org/translate/) and standard protein blast at NCBI website was 
performed. 
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3.6 Statistical analysis 
 
Utilizing GraphPad Prism5 (GraphPad software) statistical significance was 
determined by unpaired, one-way analysis of variace (ANOVA) with Bonferroni’s 
multiple comparison test (for more than two groups) or with independent two-tailed 
student’s t-test (for two groups). Significance was set at P < 0.05; 0.01; 0.001 and 
were indicated with an asterix (*, **; ***) respectively. All data are expressed as mean 
± SEM. Graphical design was conducted with Adobe Illustrator.  
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4 Results 
4.1 α4β7 Downregulation on CD8+ T cells is a unique event upon 
poly (I:C) recognition 
 
It has been shown in our laboratory that upon poly (I:C) treatment in vitro 
CD8+ T cells exhibit a marked decreased expression of α4β7 expression. As poly (I:C) 
is known to trigger the production of type I interferon upon signaling through TLR3, 
we further assessed the role of type I interferon in poly (I:C)-mediated α4β7 
downregulation. To examine this, we utilized splenocytes from IFNAR-1-deficient 
mice. IFNAR-1-deficient splenocytes lack one of the receptors for type I interferon 
that leads to dysfunction in transmitting the IFN signal into the cell. We cultured 
wild-type and IFNAR-1-deficient splenocytes with poly (I:C) 24 h and analyzed the 
expression of α4β7 and CD69 on CD8+ T cells by flow cytometry. Additionally, 
incubation of splenocytes with other TLR stimuli such as CpG type B and R848, 
TLR9 and TLR7 agonists, was also performed as positive controls.  
Result of the in vitro experiment demonstrated that all TLR ligands are able to induce 
α4β7 downregulation on CD8+ T cells in splenocyte culture (Figure 4.1, left panel). 
In contrast, in IFNAR-1-deficient splenocytes this downregulation was markedly 
reduced upon stimulation with poly (I:C) and R848 (Figure 4.1, shaded area in the left 
panel). Furthermore, CpG impaired α4β7 expression CD8+ T cells in 
IFNAR-1-deficient splenocytes similarly as in the wild-type splenocytes. CpG type B 
has been shown to poorly induce IFN. Moreover, Heidegger et al. (submitted) has 
demonstrated IL-6 is essential in CpG-mediated α4β7 downregulation.  
As control for proper immune activation in the experiment, splenocytes were also 
stained for CD69 (Figure 4.1, right panel), which is an early activation marker that is 
rapidly upregulated in various type of immune cells upon type I IFN-dependent 
immune activation (Kamphuis et al., 2006). The flow cytometry analysis 
demonstrated that poly (I:C) and R848 induced a significant upregulation of CD69 on 
CD8+ T cells in wild-type splenocytes whereas this upregulation was entirely 
abolished on CD8+ T cells in IFNAR-1-deficient splenocytes, which confirmed the 
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dysfunction of IFN signaling in these splenocytes. As expected, CD69 on T cells was 
not upregulated upon stimulation with CpG in wild-type and IFNAR-1-deficient 
splenocytes. It is however interesting to note that the upregulation of CD69 on T cells 
was not a prerequisite for the changes in α4β7 expression.  
In summary, although decrease of α4β7 on CD8+ T cells in IFNAR-1-deficient 
splenocytes was not entirely abrogated, this experiment indicates that poly (I:C) and 
R848-mediated α4β7 downregulation is IFN-dependent. 
 
 
Figure 4.1: α4β7 downregulation following poly (I:C) and R848 in vitro stimulation is dependent 
on IFN-α  (left panel). Splenocytes from wild-type (C57BL/6) and IFNAR-1-deficient mice were 
treated for 24 h with different TLR ligands. The expression of the early activation marker CD69 
(right panel) and α4β7 were measured on CD8+ T cells by flow cytometry. 
 
4.1.1 Recombinant IFN-α modulates α4β7 expression in a dose-dependent 
manner 
To further evaluate the potential of type I IFN to modulate surface expression of α4β7, 
we next stimulated splenocytes for 24 h with different concentrations of recombinant 
mouse-IFN-α and analyzed subsequently α4β7 expression on CD8+ T cells by flow 
cytometry.  
Flow cytometry analysis of CD8+ T cells displayed an IFN-α-dose-dependent 
downregulation of α4β7 expression on CD8+ T cells in splenocyte culture. A marked 
decrease of α4β7 expression emerged at a dose of 102 U/ml. This decrease reached 
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its peak at 103 U/ml (Figure 4.2, panel C). At this dose, the α4β7 expression level on 
CD8+ T cells has declined approximately 50% in comparison with the untreated 
splenocytes. Interestingly, a higher concentration than 103 U/ml did not lead to a 
definite further downregulation of α4β7 expression indicating a maximum signaling at 
103 U/ml. Moreover, higher IFN-α concentration correlated with a higher CD69 
expression on CD8+ T cells with the highest MFI at 105 U/ml (data not shown).  
We next performed a time-course experiment to determine whether longer incubation 
of splenocytes with recombinant mouse-IFN-α leads to more impairment of α4β7 
expression. Splenocytes were cultured with IFN-α (103 U/ml) for 24 h and 48 h prior 
to flow cytometry analysis.  
The result of the experiment demonstrated that longer incubation time than 24 h 
indeed induced further downmodulation of α4β7 expression on CD8+ T cells (Figure 
4.2, panel D). However, it seemed that the untreated CD8+ T cells lost their α4β7 
expression after 48 h. To conclude, we discovered that recombinant IFN-α, when 
cultured on splenocytes, is able to downregulate α4β7 expression on CD8+ T cells in 
a dose-and time-dependent manner. 
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Figure 4.2: Recombinant IFN-α  decreases α4β7 expression on CD8+ T cells in a dose-
dependent manner. Splenocytes were incubated with different concentrations of recombinant 
mouse IFN-α  for 24 h and analyzed by flow cytometry. Expression of α4β7 after IFN-α  treatment 
(A, B) was dose-dependent (C). A time-course experiment showed a downregulation of α4β7 
expression after 24 h and 48 h (D). CpG, a TLR9 agonist, was used as positive control for α4β7 
downregulation.  
 
4.1.2 The cytokines IL-12, IL-1β and IL-6 do not synergize with IFN-α in 
regulation of α4β7 expression  
The next question to be examined was whether other cytokines contribute or 
synergize with IFN-α in controlling α4β7 expression. To examine this, splenocytes 
were co-cultured with the cytokines IL-1β, IL-12 and IL-6 in presence or absence of 
IFN-α. Additionally, CpG was used as positive control in the experiment.  
In the absence of IFN-α the incubation of the splenocytes with the cytokines IL-1β, 
IL-12, IL-6 did not alter α4β7 expression (Figure 4.3). However, this stood in contrast 
to previous in vitro studies in our laboratory that pointed out the role of IL-6 in CpG-
mediated α4β7 downregulation. 
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Figure 4.3: The cytokines IL-12, IL-1β  and IL-6 do not alter α4β7 expression. Splenocytes were 
incubated for 24 h with IFN-α  or with a combination of proinflammatory cytokines (100 ng/ml). 
CpG, a TLR9 agonist, was used as positive control for α4β7 downregulation.  
 
4.1.3 Decrease of α4β7 expression on CD8+ T cells upon IFN-α stimulation is 
most pronounced among other cell adhesion molecules 
Previous experiments in the last sections have revealed that α4β7 expression is 
impaired upon stimulation by IFN-α. In the next study, we wanted to characterize 
further whether the downmodulation of α4β7 expression is a unique event among 
other cell adhesion molecules upon immune activation by IFN-α. We examined 
several cell adhesion molecules that are known to be expressed on CD8+ T cells.  
CD62L or L-selectin is an important cell adhesion molecule for lymphocyte homing 
into the peripheral lymph nodes that is highly expressed on naïve T and B cells. 
LFA-1, also known as αLβ2, is an integrin that has been shown to be essential in 
CD8+ T cell activation (Li et al., 2009). CD31 is a glycoprotein expressed on many 
types of cells including naïve CD8+ T cells that induces integrin-mediated adhesion. 
CCR7 is a chemokine receptor that is expressed on naïve as well as on central 
memory but not effector memory T cells and it has been described as an important 
molecule to migrate into the lymph nodes and into the splenic white pulp region 
(Forster et al., 1999). CCR9 is a chemokine receptor important for the homing to the 
small intestine and is expressed mainly on naïve CD8+ T cells and gut-homing T 
cells, but barely on naïve CD4+ T cells (Carramolino et al., 2001). CD44 is a 
glycoprotein that is highly expressed on memory T cells and at a low level on naïve T 
cells. CD29, a β1 integrin, can pair with α4 and plays a role in the migration of T cells 
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into the bone marrow. Cutaneous lymphocyte-associated antigen (CLA) is a 
glycoprotein expressed preferentially in skin-homing memory T cells. 
We cultured splenocytes with IFN-α for 24 h and performed subsequently flow 
cytometry analysis of the expression of the cell adhesion molecules CD62L, LFA-1, 
CD31, CCR7, CCR9, CD44, CLA, CD29 on CD8+ T cells.  
Whereas no changes in expression of CCR7, CD44, CLA could be observed, flow 
cytometry analysis showed that CD62L expression is slightly decreased upon 
activation by IFN-α (Figure 4.4). This finding corresponds with the result of 
Hamman A. et al (2000). They reported a rapid downregulation of CD62L upon 
activation by anti-CD3 followed by a decreased migration into the lymph nodes. 
A very modest decrease in CD29 expression and slight increase in CD31 and LFA-1 
on CD8+ T cells were observed. However, the most pronounced alteration in surface 
expression was measured for α4β7 expression. Interestingly, CCR9, which is a 
chemokine receptor that is important for the migration into the small intestine, 
especially to duodenum, exhibited no alteration in its expression after stimulation with 
IFN-α. This experiment indicated that the downregulation of α4β7 expression on naïve 
CD8+ T cells upon IFN-α stimulation is a unique event among cell adhesion 
molecules expressed on T cells. 
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Figure 4.4: No decrease in expression of other cell adhesion molecules on CD8+ T cells after 
IFN-α  treatment. Splenocytes were incubated with IFN-α  for 24 h prior to analysis by flow 
cytometry for α4β7, CCR9, CD44, CD29, CD62L, CCR7, CD31, LFA-1 and CLA expression on 
CD8+ T cells. Histograms of several examined cell adhesion molecules with expression 
changes after IFN-α  treatment are shown in panel A (grey solid area is the untreated 
splenocytes and black line is the IFN-α  treated splenocytes). Comparison of all analyzed cell 
adhesion molecules is depicted in panel B.  
 
4.1.4 IFN-α induces α4β7 downregulation on purified T cells 
We next investigated whether the downregulation is a direct effect or mediated by 
different cell types. CD3+ cells were sorted with a negative isolation kit and cultured 
with IFN-α for 24 h prior to flow cytometry analysis. As a positive control, we also 
cultured whole splenocytes with IFN-α and CpG for 24 h. Previous experiments in 
our laboratory showed that CpG was able to induce downregulation of α4β7 
expression on CD8+ T cells in splenocyte culture, however it failed to do so in a 
culture of purified T cells. This in vitro finding suggested that naïve T cells lack 
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functional TLR9, despite the report by Cottalorda A. et al. (2006) that mRNAs of 
TLR9 can be detected in naïve T cells.  
Confirming previous experiments, flow cytometry analysis showed that CpG led to a 
decrease of α4β7 expression on CD8+ T cells in splenocyte culture (Figure 4.5), 
whereas this effect was totally abrogated in purified T cells. In contrast, in the 
presence of IFN-α, α4β7 expression on purified CD8+ T cells remained as low as on 
CD8+ T cells in splenocyte culture. Hence, IFN-α could act directly on T cells to 
trigger α4β7 downregulation and this could take place without participation of other 
cell populations.  
 
 
Figure 4.5: IFN-α  downregulates α4β7 on CD8+ T cells in a direct manner. Splenocytes and 
purified T cells were incubated with IFN-α  (103 U/ml) for 24 h prior to analysis by flow 
cytometry for α4β7 expression on CD8+ T cells. The percentage of T cell purity is 92.7% (gated 
on CD3+). 
 
4.1.5 Poly (I:C) decreases α4β7 expression on CD8+ T cells in vivo  
To investigate the role of poly (I:C) in vivo in modulating α4β7 expression, we treated 
mice two times intraperitoneally with poly (I:C) on the first and third day of the 
experiment. On the fifth day secondary lymphoid organs such as spleen, peripheral 
and mesenteric lymph nodes, were isolated and cells were stained with fluorescence-
coupled antibodies against CD3, CD8, and α4β7.  
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We observed that untreated CD8+ T cells in mesenteric lymph nodes displayed a 
higher α4β7 expression compared with CD8+ T cells in peripheral lymph nodes and 
spleen. Moreover, in mice treated with poly (I:C) α4β7 expression on CD8+ T cells 
was significantly diminished in spleen, as well as in peripheral and mesenteric lymph 
nodes (Figure 4.6). This supported previous in vitro findings in our laboratory. This 
downregulation could also be seen in CD4+ T cells (data not shown).  
To summarize, our experiment showed that poly (I:C) recognition in vivo also led to 
α4β7 downregulation on naïve T cells. 
 
 
Figure 4.6: Poly (I:C) decreases α4β7 expression on CD8+ T cells in vivo. Mice (n=5/group) were 
treated intraperitoneally with poly (I:C) (2x 230 µg; 5 days and 2 days prior to isolation). Spleen, 
peripheral (PLN) and mesenteric lymph nodes (MLN) were analyzed by flow cytometry for α4β7 
expression on CD8+ T cells. 
 
Our in vitro finding with the IFNAR-1-deficient splenocytes encouraged us to further 
explore the role of type I interferon in modulating α4β7 expression on CD8+ T cells in 
vivo. To investigate this, wild-type and IFNAR-1-deficient mice were treated 
intraperitoneally with poly (I:C) on the first and third day of the experiment. On the 
fifth day, spleen, peripheral lymph nodes, mesenteric lymph nodes and Peyer’s 
patches were isolated and we subsequently analyzed α4β7 expression on 
CD8+ T cells via flow cytometry.  
Consistent to the result in Figure 4.6, we observed a nearly two-fold decrease of α4β7 
expression on CD8+ T cells in peripheral and mesenteric lymph nodes of the 
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wild-type mice upon treatment with poly (I:C) (Figure 4.7). Though less pronounced, 
we also noticed a marked decrease of α4β7 expression on CD8+ T cells in the Peyer’s 
patches of the wild-type mice. By contrast, α4β7 expression on CD8+ T cells was not 
altered in the secondary lymphoid organs of the IFNAR-1-deficient mice treated with 
poly (I:C) compared with untreated IFNAR-1-deficient and wild-type mice. This stood 
somewhat in contrast to the previous in vitro experiment (Figure 4.1). Hence, this 
experiment demonstrated that in vivo the impaired α4β7 surface expression appeared 
to be totally dependent on IFN-signaling, whereas in vitro other signaling pathways 
might contribute to α4β7 regulation.  
To summarize, our in vivo experiment revealed that upon poly (I:C) injection, α4β7 
expression on naïve CD8+ T cells is downreregulated and this absolutely requires an 
intact type I IFN signaling.  
 
 
Figure 4.7: α4β7 downregulation is abolished in IFNAR-1-deficient mice following poly (I:C) 
injection. Mice (n=5/group) were treated intraperitoneally with poly (I:C) (2x 230 µg; 5 days and 
2 days prior to isolation). Spleen, peripheral lymph nodes (PLN), mesenteric lymph nodes 
(MLN) and Peyer’s patches (PP) were analyzed by flow cytometry for α4β7 expression on CD8+ 
T cells. 
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4.1.6 α4β7 expression on CD8+ T cells is downregulated in mice treated with 
IFN-α 
To confirm the conducted in vitro studies and the in vivo role of IFN-α in 
poly (I:C)-mediated α4β7 expression, we next investigated whether IFN-α impairs 
α4β7 expression in vivo as was seen with poly (I:C) (Figure 4.6, Figure 4.7). We 
challenged mice for three days with 10 µg recombinant IFN-α intraperitoneally and 
analyzed α4β7 expression on CD8+ T cells on the fourth day.  
Flow cytometry analysis demonstrated that in all examined secondary lymphoid 
organs of mice treated with IFN-α, α4β7 expression levels on CD8+ T cells decreased 
at least two-fold compared to untreated mice (Figure 4.8, left panel). As a positive 
control of immune activation, CD69 expression on CD8+ T cells was analyzed (Figure 
4.8, right panel). IFN-α induced a significant upregulation of CD69 on CD8+ T cells in 
spleen, mesenteric and peripheral lymph nodes, confirming that the recombinant 
IFN-α was functional and the application route was sufficient to induce immune 
activation. Interestingly, untreated splenic CD8+ T cells had already a higher CD69 
expression than CD8+ T cells in the peripheral and mesenteric lymph nodes.  
 
 
Figure 4.8: IFN-α  induces α4β7 downregulation on CD8+ T cells in vivo (left panel). Mice 
(n=3/group) were treated for 3 days intraperitoneally with recombinant mouse IFN-α  
(10 µg/day). Spleen, peripheral lymph nodes (PLN), mesenteric lymph nodes (MLN) were taken 
out 24 h after the last injection and analyzed by flow cytometry for α4β7 expression on CD8+ 
T cells. CD69, an early activation marker, was used as positive control for immune activation 
by IFN-α  (right panel).  
 
statistic: t­test
C
D
69
 o
n 
N
K 
ce
lls
 
   
   
   
 (M
FI
)
MLNPLNSpleen
0
5000
10000
15000
20000
*
* *
CD69
0
200
400
600
800
MLNPLNSpleen
* *
*
Untreated
!"#$%
%&
'(
 o
n 
C
D
8+
 T
 c
el
ls
   
   
   
   
   
(M
FI
)
!"#$
Results 
 
63 
4.2 Regulation of α4β7 expression on CD8+ T cells upon virus 
recognition 
 
After scrutinizing the role of recombinant IFN-α in modulating α4β7 expression, we 
were interested to further evaluate whether viral infection would also lead to 
alteration in α4β7 expression. Upon viral infection, type I IFN is an essential factor to 
alarm neighbouring cells and to prevent other cells to be infected. To examine this, 
we used different viruses: Sendai, enchephalomyocarditis (EMCV), wild-type and 
mutant form of vesicular stomatitis (VSV) virus. The VSV DNA is known to encode 
the so-called matrix protein or “M protein” which blocks the host transcription by 
inhibiting the initiation of RNA polymerase. Moreover, it can also interfere with the 
nucleocytoplasmic transport. The mutant form of VSV (VSVmut) used in this 
experiment has a mutation in the M protein leading to its disability to inhibit the host 
gene transcriptions and nucleocytoplasmic transport. 
We incubated splenocytes with different concentrations of the viruses. After 3 h, the 
viruses were washed out of the cell culture and the splenocytes were incubated for 
24 h prior to flow cytometry analysis. As positive control for α4β7 expression, we also 
treated splenocytes with CpG and recombinant mouse IFN-α.  
Flow cytometry analysis of α4β7 expression depicted in Figure 4.9 (upper panel) 
revealed that incubation of splenocytes with Sendai virus caused a similar decrease 
in expression of α4β7 on CD8+ T cells as with recombinant IFN-α. Interestingly, the 
downregulation was not dependent on the virus concentration. Furthermore, EMCV 
induced downregulation of α4β7 expression on CD8+ T cells and in contrast to Sendai 
virus, the effect was even more pronounced when higher virus titer was used in the 
splenocyte culture. Incubation of splenocytes with VSV virus led to a very modest 
decrease of α4β7 expression by VSV. This might be due to the ability of M protein to 
inhibit nucleocytoplasmic transport, thus leading to transcriptional repression of 
cytokines. In contrast, incubation of splenocytes with the VSVmut led to significant 
alteration in α4β7 expression in a dose-dependent manner.  
Additionally, expression of CD69, an IFN-dependent early activation marker, was 
examined in the same samples (Figure 4.9, lower panel). Incubation of splenocytes 
with Sendai virus led to a higher upregulation of CD69 than with recombinant IFN-α. 
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This might be due to higher IFN-α levels produced in splenocytes incubated with 
Sendai virus. Furthermore, EMCV and VSV-treated splenocytes, like CpG-treated 
splenocytes showed no or only modest CD69 upregulation on CD8+ T cells. In 
contrast, in splenocyte culture incubated with VSVmut (106 and 107 pfu/ml) CD69 
expression on CD8+ T cells was upregulated in dose-dependent manner.  
To summarize, we demonstrated that viruses such as Sendai, EMCV and VSVmut 
could induce the downregulation of α4β7 expression on naïve CD8+ T cells in 
splenocyte culture.  
 
Figure 4.9: α4β7 is downregulated on CD8+ T cells upon incubation with virus (upper panel). 
Splenocytes were incubated for 24 h with different concentrations of virus (EMCV: 105, 106, 107 
pfu/ml; SeV: 10, 100, 250 U/ml; VSV: 105, 106, 107 pfu/ml; VSVmut M31R: 105, 106, 107 pfu/ml). 
CpG and IFN-α  were used as positive controls. CD69, an IFN-α-dependent early activation 
marker, was used as control for immune reaction (lower panel). 
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4.2.1 Virus-induced α4β7 downregulation is less pronounced on purified 
T cells 
In the next study, we assessed the impact of the viruses on purified T cells. 
Splenocytes and purified T cells were incubated with Sendai virus, EMCV, VSV and 
VSVmut for 3 h before the viruses were washed out of the cell culture. After 24 h of 
incubation, the α4β7 expression on CD8+ T cells was measured by flow cytometry. As 
positive control for the downregulation, we cultured splenocytes and purified T cells 
with IFN-α. Additionally, we stimulated the splenocytes and T cells with CpG as a 
positive and negative control, respectively.  
Consistent with previous result described in Figure 4.9, in splenocyte culture α4β7 
expression on CD8+ T cells was decreased in the presence of EMCV, Sendai and 
VSVmut, whereas incubation with VSV led to a modest decrease (Figure 4.10, upper 
panel). Strikingly, the decrease of α4β7 expression on CD8+ T cells was markedly 
less pronounced on purified T cells incubated with the viruses. As expected, 
stimulation with recombinant IFN-α inhibited α4β7 expression on CD8+ T cells in 
splenocyte culture as well as on purified T cell culture. Unexpectedly, stimulation of 
purified T cells with CpG still induced a decrease of α4β7 expression, although less 
marked than in splenocyte culture. This might be possibly due to some cell 
populations (e.g. DCs) existing in the 94%-purified T cells that were still able to 
induce TLR9 signaling. In a better purified T cell population we would therefore 
expect that the downregulation of α4β7 expression by the viruses would even be 
more insignificant.  
Additionally, we performed flow cytometry analysis of CD69 expression (Figure 4.10, 
lower panel). Confirming the previous experiment, incubation with Sendai and 
VSVmut led to an upregulation of CD69 on CD8+ T cells in splenocyte culture 
whereas EMCV and VSV did not induce CD69 expression. In contrast, CD69 
expression on purified CD8+ T cells did not significantly increase upon stimulation 
with Sendai virus. Furthermore, in purified T cells VSVmut failed to induce CD69 
expression. Since the production of type I IFN was necessary to induce CD69 
upregulation on T cells, this finding would suggest that the recognition of the VSVmut 
was mediated by other immune cells and other immune cells than T cells were 
responsible for the initiation of type I IFN production.  
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In summary, we observed a less pronouced α4β7 downregulation on purified naïve 
CD8+ T cells than in splenocyte culture.  
 
 
Figure 4.10: α4β7 downregulation by virus is less pronounced on purified T cells (upper panel). 
Splenocytes and purified T cells (94.1 % after purification) were incubated for 24 h with viruses 
(SeV 250 U/ml, EMCV 107 pfu/ml, VSV 107 pfu/ml, VSVmut M31R 107 pfu/ml). Splenocytes and 
purified T cells were gated based on their expression of CD3, CD8 and α4β7. CD69, an IFN-α-
dependent early activation marker, was used as control for immune reaction (lower panel). 
Statistical analysis to compare a same group (e.g. CpG) in the two different conditions 
(splenocyte culture versus purified T cells) was perfomed using independent two-tailed 
student’s t-test. 
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4.2.2 IFN-α and IL-6 are detected in supernatant of virus-treated splenocytes 
To affirm the role of IFN-α in the virus-mediated downregulation of α4β7 expression, 
we examined the presence of IFN-α in the supernatants of splenocyte culture 
incubated with the viruses. Additionally, IL-6 concentration was also measured. 
The analysis of IL-6 ELISA data (Figure 4.11, left panel) showed that incubation of 
splenocytes with CpG induced a four-fold increase of IL-6 compared to the untreated. 
This was expected, since it is known that CpG trigger IL-6 production upon NF-κB 
activation. Interestingly, incubation of splenocytes with the highest viral titer of EMCV 
(107 U/ml EMCV in 4.105 splenocytes) led to a large production of IL-6 comparable to 
splenocytes incubated with CpG, whereas IL-6 level in supernatant of Sendai, VSV, 
and VSVmut-treated splenocytes remained as low as in the untreated condition.  
Figure 4.11 (right panel) showed a significant large amount of IFN-α produced in the 
supernatant of splenocytes cultured with Sendai virus. Furthermore, supernatant 
cultured with VSVmut virus showed a correlation between increasing amount of viral 
titer and IFN-α production. In the supernatant of splenocytes treated with highest 
amount of EMCV virus, we could detect a slight increase of IFN-α production. In 
contrast, we could not detect IFN-α in the supernatant of splenocytes cultured with 
VSV. This could be correlated to our previous finding (Figure 4.9), in which we 
observed a less pronounced α4β7 downregulation on CD8+ T cells in splenocyte 
culture treated with VSV virus. The inhibition of nucleocytoplasmic transportation by 
M protein might be the cause of the absence of IFN-α production.  
To summarize, in the supernatant of splenocytes treated with Sendai and VSVmut 
virus we could detect the presence of IFN-α, whereas in the supernatant of 
splenocytes incubated with EMCV a substantial amount IL-6 could be measured.  
Results 
 
68 
 
Figure 4.11: EMCV, SeV, VSVmut-treated splenocytes produce large amount of IL-6 and IFN-α , 
respectively. Supernatants of 24-hour with virus cultured splenocytes were analyzed by IL-6 
(left panel) and IFN-α  ELISA (right panel).  
 
4.2.3 Blocking the IL-6 or type I IFN receptor inhibits α4β7 downregulation  
To confirm the role of IL-6 and IFN-α in virus-induced decrease of α4β7 expression, 
we incubated purified T cells with supernatants of splenocytes incubated with EMCV 
and Sendai virus. We added blocking antibody against IL-6 or IFNAR-1 or a 
combination of both to the purified T cells. As negative control for α4β7 
downregulation, we added supernatant of untreated splenocytes to the purified 
T cells. As positive control for IL-6-mediated α4β7 downregulation, purified T cells 
were cultured in the supernatant of splenocytes treated with CpG.  
Supernatants of CpG and virus-cultured splenocytes without blocking antibodies 
induced a decrease of α4β7 expression, supporting that soluble factors play a role in 
inducing changes in α4β7 expression (Figure 4.12). The decrease was significantly 
reduced when IL-6 antibody was present in CpG and EMCV-treated conditions and 
addition of blocking antibody against IFNAR-1 did not improve the reduction in these 
conditions. In contrast, blocking antibody against IFNAR-1 but not against IL-6 
significantly inhibited the downregulation of α4β7 expression on CD8+ T cells in 
Sendai-treated supernatant.  
With this experiment we could confirm the role of IFN-α in modulating α4β7 
expression on CD8+ T cells, when immune cells are challegend by Sendai and 
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VSVmut virus. Furthermore, we could also demonstrate that secretion of IL-6 by 
immune cells treated with EMCV virus is essential for α4β7 downregulation on naïve 
CD8+ T cells. 
 
 
Figure 4.12: Blocking IL-6 and IFNAR-1 significantly inhibit virus-mediated α4β7 downregulation 
on CD8+ T cells. Purified T cells (250.000 cells/well, triplicate per group) were cultured for 24 h 
with supernatant of untreated splenocytes (untreated group, white bars) or with supernatant of 
virus-treated splenocytes in presence or absence of antibody against IL-6 (5 µg/ml) and IFN-α  
(1.5 µg/ml). CpG was used as positive control. Cells were stained for CD3, CD8 and α4β7.  
 
4.3 IFN-α-stimulated splenocytes have an impaired migration into the 
gut-associated lymphoid organs 
 
After revealing the ability of IFN-α to modulate α4β7 expression, our next question 
was whether the decrease of expression of α4β7 alters the migration pattern of naïve 
T cells into the secondary lymphoid organs. To test this, splenocytes were cultured 
for 48 h in the presence and absence of IFN-α. We then labeled the untreated and 
IFN-α-treated splenocytes with eFluor670 and CFSE, respectively. Both are 
fluorescent cell staining dyes that bind cellular proteins and are equally distributed 
between daughter cells when the cells divide. The differently labeled splenocytes 
were then mixed in 1:1 ratio and transferred retroorbitally into nine mice. 24 h after 
adoptive transfer, spleen, Peyer’s patches, peripheral and mesenteric lymph nodes 
were isolated from five mice. We then analyzed the percentage of the fluorescent-
stained splenocytes by flow cytometry. 
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Flow cytometry analysis showed that 24 h after of adoptive transfer, homing of the 
differently labeled splenocytes into the spleen did not differ (Figure 4.13, panel A 
and B), confirming that the migration of immune cells into the spleen is not 
dependent on α4β7 expression. Furthermore, migration of IFN-α-treated splenocytes 
into the peripheral lymph nodes was moderately reduced. By contrast, the trafficking 
of IFN-α-treated splenocytes into mesenteric lymph node was markedly reduced 
compared with untreated splenocytes. Most importantly, the effect of reduced 
migration of IFN-α-treated splenocytes was most pronounced in the Peyer’s patches.  
Four days after the adoptive transfer, flow cytometry analysis of the rest four mice 
showed that, the difference in migration pattern between IFN-α-treated and untreated 
splenocytes was abolished (Figure 4.13, panel C). This suggested that the reduced 
migration into the GALT is a transient mechanism upon immune stimulation by IFN-α. 
In this experiment we demonstrated that IFN-α-mediated α4β7 downregulation 
induced a markedly reduced migration of the splenocytes into the Peyer’s patches 
and mesenteric lymph nodes and to a lesser extent into the peripheral lymph nodes. 
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Figure 4.13: IFN-α-treated splenocytes have a temporary impaired migration into the 
mesenteric lymph nodes and Peyer’s patches. Untreated and IFN-α  treated splenocytes (10 
millions cells each group) were labeled with eFluor670 and CFSE respectively and injected into 
mice (n=9) in 1:1 ratio. After 24 h, five mice were sacrificed and labeled splenocytes in the 
spleen, peripheral lymph nodes (PLN), mesenteric lymph nodes (MLN) and Peyer’s patches 
(PP) were tracked by flow cytometry and analyzed by FlowJo software (A). Homing index was 
calculated and quantified with the statistical program GraphPad Prism5 (B). After four days, 
labeled splenocytes in the rest of other four mice were analyzed and homing index was 
calculated (C).   
 
4.4 Cloning the integrin genes 
 
To clone the genes into the retroviral vector pMP71, we firstly performed PCR to 
amplify the genes for the integrins. Figure 4.14 depicted the result of gel 
electrophoresis after PCR. The expected size for ITGB1 and ITGB7 (the genes for β1 
and β7) was at 2.4 kilo basepairs and for ITGA4 (the gene for α4) was at 3 kilo 
basepairs. As clearly showed in the figure, we could amplify DNA sequences at the 
right size of the integrin genes. 
We then performed digestion and ligation of the genes with the pMP71 vectors prior 
to transformation into E.coli to amplify the ligated vectors. E.coli resistant to ampicillin 
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were screened for the integrin genes using colony PCR before sending for 
sequencing. 
 
            
 
 
 
 
 
 
 
 
                     Figure 4.14: PCR product applied on gel.   
                    1 Kb GeneRuler from Fermentas was used (in base pairs, bp).  
 
4.4.1 Validation of insertion of the integrin genes in the vector pMP71 
Figure 4.15 represents vectors, which were sent to sequencing and have shown to 
have the right sequence of the genes. To verify the insertion of the integrin genes, 
test digestion with EcoRI and NotI was performed and resulted in excision of the 
genes from the vector at the correct size (2.4 Kb for ITGB1 and ITGB7, 3 Kb for 
ITGA4). pMP71-GFP was used to verify correctness of the digestion. As expected 
the gene for GFP at 700 bp could be detected.  
 
 
Figure 4.15: Image of gelelectrophoresis of vector digestion. 1 µg of vectors containing the 
integrin genes or GFP was digested with EcoRI and NotI.1 Kb ladder DNA marker from Axygen 
Biosciences was used (in base pairs). 
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4.4.2 Transfection and transduction of the integrin genes 
Using calcium-phosphate transfection method, we could induce the expression of 
GFP, α4 and β1 in Plat-E cells. To note, we used 18 µg pMP71-GFP and 40 µg for 
pMP71-ITGA4 or pMP71-ITGB1. Untransfected Plat-E did not express detectable 
amount of the integrins α4 and β1 (data not shown). Transfection efficiency of GFP 
was 66.7 % whereas the integrins α4 and β1 show an upregulation of cell surface 
expression of 48.2 % and 11.9 %, respectively (Figure 4.16, panel A upper graph).  
When we checked transduction efficiency, we obtained 81.9% GFP-positive primary 
T cells, whereas the integrins α4 and β1 are 12.3% and 37.8 % expressed on cell 
surface of the T cells (Figure 4.16, panel A lower graph). However, β1 was already 
expressed (22.5%) in untransduced T cells (Figure 4.16, right graph on panel B). 
 
Figure 4.16: Transfection of Plat-E (panel A upper panel) with pMP71-GFP, pMP71-ITGA4 and 
pMP71-ITGB1 and transduction with viral supernatant of Plat-E (panel A lower panel). Results 
of transfection of 18 µg of pMP71-GFP and 40 µg pMP71-ITGA4 and pMP71-ITGB1 are shown in 
the figure. Untransduced primary T cells were stained with antibodies against α4 and β1 
(panel B). 
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For β7 integrin we firstly did not detect an increased of cell surface expression after 
transfection of Plat-E cells. However, when we performed intracellular staining, we 
could detect β7 expression within the cells (Figure 4.17). This intracellular staining 
confirmed the functionality of the retroviral vector containing β7. Unlike α4 and β1, it 
seemed that in Plat-E cells β7 does not have pairing subunit (either α4 or αE), which 
hampers the transportation of β7 onto the cell surface. Due to the low transfection 
efficiency, we could not detect expression of β7 on the surface of primary T cells or 
intracellularly (data not shown).  
 
 
 
 
 
 
 
 
 
To summarize, we demonstrate that the cloning of the integrin genes into the 
retroviral vector pMP71 results in a properly functioning retroviral vector expressing 
the integrin proteins in the retroviral packaging cell line Plat-E. We could also show 
that the transduction into primary T cells works best with the retroviral vector pMP71 
containing the GFP gene and to a lesser extent α4 and β1 genes. The transduction of 
primary T cells with the integrin genes should therefore be optimized. Higher 
transfection efficiency could be reached using shorter time of incubation to form 
Ca2+ -DNA-phosphate complexes. Also, longer time of Plat-E incubation after 
transfection may help to produce higher titer of retroviruses, since the integrin genes 
are larger than GFP gene. Long-term cell culture of Plat-E or T cell lines may impact 
transfection and transduction efficiency, respectively. pH of transfection buffer should 
also be checked regularly. Furthermore, the use of different assays such as Western 
Figure 4.17: Transfection of Plat-E cells with retroviral vector 
containing β7 integrin gene. Cell surface and intracellular staining of 
β7 integrin are depicted in left and right panel, respectively. 
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blot to detect protein expression should be taken into consideration, since fixation 
process in the intracellular staining could alter protein structure and reduce binding 
affinity of the antibody.  
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5 Discussion 
 
5.1 A novel mechanism to control migration of bystander-activated 
T cells during viral infection 
 
Although much is known about the migration of effector T cells during viral infection, 
the migration of the bystander-activated T cells during this period remains elusive. 
These are T cells defined as antigen-unspecific T cells, which upon stimulation (e.g. 
bacterial or viral infection) undergo phenotypic and functional changes independent 
from the specific T cell receptor (TCR) stimulation (Bangs et al., 2006). These 
alterations, which can be mediated by cytokines, may facilitate the bypass of control 
checkpoints.  
 
5.1.1 Bystander-activated T cells: implication in protective immunity and 
autoimmunity  
 
The role of bystander-activated T cells in protective immunity or autoimmunity has 
not been yet completely understood. Supporting the protective immunity model, using 
LMCV-specific TCR transgenic mice in which CTL-mediated antiviral effector is 
exclusively mediated by contact-dependent perforin-mediated cytotoxicity, Ehl et al.  
showed that upon infection with a pathogen unrelated to LMCV, the nonspecific 
activated T cells are capable of providing an antiviral response (Ehl et al., 1997). 
They also demonstrated that bystander activation with unrelated virus is not sufficient 
to induce diabetes, whereas LMCV infection can promote diabetes in these 
transgenic mice.  
However, there are also evidences for the role of bystander-activated T cells in 
autoimmune diseases. In fact, viral infections, which may induce nonspecific 
activation, have been related to the induction of autoimmune diseases (Kim et al., 
2006). For example, a study by Nogai at al. reveals that activation of autoreactive 
T cell in TCR-transgenic mice upon LPS provoked the development of experimental 
autoimmune enchephalitis (EAE), a murine model for multiple sclerosis (Nogai et al., 
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2005). This finding could be recently verified by another group, where they 
demonstrated that T cells deficient in TLR4, which is the receptor for LPS, were not 
able to promote EAE (Reynolds et al., 2012).   
Considering that bacterial or viral infections are a common occurance, it is rather 
striking that autoimmune diseases are not the general pattern. Although some 
correlations to genetical and environmental factors have been described (Fasano 
and Shea-Donohue, 2005), which affect the severity of autoimmune diseases, we 
hypothesize that mechanisms for controlling migration of bystander-activated T cells 
during infection may exist.  
 
5.1.2 The dual function of the integrin α4β7  
 
The migration of naïve T cells and skin-specific central memory T cells into the 
peripheral lymph nodes is governed by a set of cell adhesion molecules which is 
distinct from the set of cell adhesion molecules expressed on the skin-specific 
effector T cells. In contrast, intestinal-specific effector T cells and naïve T cells 
require the expression of the homing receptor α4β7 to enter the gastrointestinal tract 
and the GALT. The difference in utilization of integrin α4β7 relies exclusively on the 
state of the expression on naïve T cells (low level) and intestinal effector T cells (high 
level). Moreover, in comparison to other integrins, α4β7 is unique due to its ability to 
mediate rolling and firm adhesion (Gorfu et al., 2009). 
As a peripheral tissue with the largest surface area, the gastrointestinal tract is a 
home for a vast numbers of commensal bacteria and thus represents the largest 
source of non-self antigens, a strict regulation of α4β7 expression is therefore vital to 
prevent mistrafficking.  
 
5.1.3 Downregulation of α4β7 upon viral infection is mediated by IFN-α or IL-6 
 
Consistent with the bacterial infection study perfomed by Heidegger et al. 
(manuscript submitted), we observe that α4β7 expression is negatively regulated on 
naïve CD8+ T cells in mice receiving poly (I:C). Poly (I:C) is structurally similar to a 
double-stranded RNA and can be detected by TLR3 or the cytosolic MDA-5 that also 
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detect viral double-stranded RNA. Hence, poly (I:C) elicits the same signaling 
pathway as in viral infections, which makes it attractive for its utilization as viral 
infection model.  
A similar downmodulation of α4β7 was described in human T cell clones, either upon 
specific recognition of alloantigens, with immobilized anti-CD3 mAbs or soluble 
anti-CD43 (Hernández-Caselles et al., 1996). In their study, they demonstrated that 
the membrane expression of α4 integrin can be regulated by TCR/CD3-dependent as 
well as independent signals. In agreement with their study, our observation could 
extend the knowledge of the α4β7 regulation on primary naïve T cells upon immune 
stimulation in mice. 
Interestingly, stimulation of splenocytes from IFNAR-deficient mice with poly (I:C) and 
R848 induced partial reduction of the observed α4β7 downregulation in wild-type 
splenocytes, suggesting a significant role for type I IFN, whereas the effect of CpG 
does not seem to be type IFN-dependent. Indeed, Heidegger et al. could show that 
IL-6 plays a dominant role in α4β7 regulation upon CpG recognition.   
 
5.1.3.1 Absolute requirement of type I IFN signaling to induce α4β7 downregulation in 
vivo 
In contrast to our in vitro data, α4β7 downregulation on T cells is completely inhibited 
in IFNAR knockout mice upon injection of poly (I:C), indicating an absolute 
requirement of type I IFN signaling in induction of α4β7 modulation when examined in 
vivo. The difference may due to different response to poly (I:C) between splenic and 
peritoneal APCs. In the in vivo experimental setting, upon intraperitonal injection the 
uptake of poly (I:C) is perfomed by the peritoneal APCs, whereas in vitro splenic 
APCs are responsible for the detection. Indeed, several studies have shown that the 
splenic and peritoneal macrophages exhibit distinct alterations upon stimulations 
(Shortman and Wu, 2004; Stout and Suttles, 2005; Olsson and Sundler, 2006). Study 
conducted by Liu et al. demonstrates that splenic macrophages express higher 
co-stimulatory molecules and cytokines, whereas peritoneal macrophages express 
higher level of TLR2 and TLR4 and are superior in phagocytosis (Liu et al., 2006). 
Hence, depending upon which macrophages recognize poly (I:C), production of 
additional cytokines may be induced by splenic macrophages.  
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5.1.3.2 IFN-α directly induces α4β7 downregulation on naïve CD8+ T cells in a time 
and dose-dependent manner 
In further experiments we validated the fact that IFN-α is able to modulate α4β7 
expression on splenic CD8+ T cells in vitro in a time- and dose-dependent manner. 
Interestingly, higher dosage of IFN-α than 103 U/ml did not lead to an additional 
significant decrease of α4β7 expression, although CD69 expression was steadily 
enhanced. When modulation of α4β7 expression on purified T cells and T cells in 
splenocyte culture was compared, it is apparent that the level of decreased 
expression is quite similar, suggesting that intrinsic type I IFN signaling solely in 
T cells at a concentration threshold of 103 U/ml is sufficient to induce the alteration. 
Interestingly, α4β7 expression on T cell surface could not be completely shut off with 
a higher dosage of IFN-α. One possibility would be that it has some functions during 
T cell activation. 
Corresponding to the in vitro experiment, we could further demonstrated that IFN-α 
can lead to the modulation of α4β7 expression on CD8+ T cells in vivo, suggesting that 
the alteration is physiologically relevant. Downregulation of the α4 subunit on primed 
T cells was described in the analysis of multiple sclerosis patients receiving IFN-β 
treatment (Muraro et al., 2000). However, in their study no changes in α4 expression 
on unprimed naïve T cells was observed and whether β7 expression is modulated on 
unprimed T cells was not shown in this study.  
 
5.1.3.3 Changes in other cell adhesion molecules on naïve CD8+ T cells upon IFN-α 
treatment 
Analysis of other cell adhesion molecule expressions upon 24h-treatment with IFN-α 
revealed that there is a slight but marked decrease of L-selectin (CD62L) expression 
on CD8+ T cells. However, this stood in contrast to a previous study by Kampuis et 
al., in which they demonstrated a minor increase of L-selectin on lymphocytes upon 
poly (I:C) injection into wild-type mice (Kamphuis et al., 2006). The difference could 
be explained by their analysis of L-selectin on total lymphocytes, which include B and 
T cells, whereas in our study we specifically surveyed the expression of L-selectin on 
CD8+ T cells. Indeed, another study evinced that IFN-α induces an upregulation of 
L-selectin on human B lymphoid Daudi cell lines and in B cell subpopulations (Evans 
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et al., 1993). Hence, the increase expression of L-selectin on B cells might mask the 
decreased expression of L-selectin on activated naïve T cells.  
In the same study by Kamphuis et al., they did not observe a downregulation of 
CD49d (α4 subunit) or upregulation of LFA-1 (CD11a/CD18). However, like 
L-selectin, CD49d and LFA-1 surface expression analyses were perfomed on total 
lymphocytes. Thus, a “masking” effect as in case of L-selectin could be the reason 
for the difference. In contrast to their study, the substanstial increase of LFA-1 
expression on CD8+ T cells in presence of IFN-α corresponded the observation in a 
systemic infection study with LMCV that is known to induce robust type I IFN 
(Merigan et al., 1977; Andersson et al., 1994, 1995; Zhou et al., 2010). 
Furthermore, a slight but significant increase of CD31 on T cells was also observed. 
CD31 is expressed on human naïve and CD8+ T cells (Stockinger et al., 1992). It was 
shown that, when CD31 is transduced into human T cell clones lacking CD31, the 
T cell clones acquire a reduced proliferation capability due to a blockage in cell cycle 
progression in G0/G1 stage (Prager et al., 2001). The CD31 upregulation on naïve 
CD8+ T cells upon IFN-α stimulation could therefore be a mechanism to inhibit 
proliferation of the bystander-activated cells. Suporting this idea, Dondi et al. 
demonstrated that resting naïve T cells delayed their entry into cell cycle after TCR 
triggering when treated with IFN-α (Dondi et al., 2003)  
Our experiment demonstrates that other cell adhesion molecules on naïve 
CD8+ T cells, such as L-selectin, LFA-1 and CD31, are also moderately regulated 
upon activation type I IFN signaling. Our observation also shows that deeper analysis 
of a specific subpopulation of lymphocytes (in our case naïve CD8+ T cells) could 
reveal different results with previous studies on whole lymphocytes, since different 
immune cell populations within lymphocytes could act differently to a specific 
cytokine such as IFN-α. Though the modulation effect is not as strong as in the case 
of α4β7, the observations on other cell adhesion molecules should not be 
disregarded, since minor alteration in their expression level on the cell surface could 
have an important function in fine-tuning how the immune cell should react to the 
environmental changes induced by IFN-α. 
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5.1.3.4 Alteration in α4β7 expression upon incubation with different viruses 
In our further extensive studies using several virus such as VSV, VSVmut, EMCV 
and Sendai, we could reproduce the same findings as with poly (I:C), in which we 
also observed downregulation of α4β7 expression on naïve CD8+ T cells. In the case 
of Sendai and VSVmut, the alteration of α4β7 expression seemed to be predominantly 
dependent on IFN-α production. Interestingly, the modulation was not 
dose-dependent in Sendai infection, whereas increasing virus titer of VSVmut led to 
an enhanced inhibition of α4β7 expression. Moreover, this correlated with the amount 
of produced IFN-α in both conditions. It seemed that low titer of Sendai virus in 
splenocyte culture was sufficient to induce robust IFN production, which 
corresponded to at least to the amount of control IFN-α (103 U/ml), since the 
downregulation was comparable. Indeed, IFN-producing Sendai virus was shown to 
be superior inducer when compared with influenza virus at the same MOI (multiplicity 
of infection) (López et al., 2003). 
Similar to CpG, α4β7 downregulation on CD8+ T cells induced by EMCV is mainly 
mediated by IL-6. Consistent with the observed result with VSVmut virus, the 
downregulation seems to be dependent on the amount of virus infecting the 
splenocytes and this amount correlates with the production of IL-6 measured in the 
supernatant. Interestingly, CD69 upregulation on T cells seems not to be a 
prerequisite for the downregulation, since EMCV infection, similar to CpG, did not 
enhanced its expression, but the alteration in α4β7 expression was still observed.  
The results obtained using different viruses support the fact that our models for 
innate immune activation using CpG and poly (I:C) mirror the effect induced by 
EMCV and Sendai virus, respectively. 
Whether the downregulation requires an active infection or only uptake was not 
adressed in our study. A study performed by López et al. with Sendai virus 
suggested that infection is needed for cytokine production by DCs, since incubation 
of DCs with UV-light-inactivated Sendai virus did not produce any cytokines (López 
et al., 2003). Supporting this, when purified T cells were incubated with virus, we 
could not observe cytokine production (data not shown) in the supernatant, indicating 
that other immune cells are the main cytokine producer upon virus challenge. Also, 
the upregulation of CD69 on purified T cells incubated with Sendai or VSVmut virus 
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was almost abolished, indicating that the production of type I IFN, at least in the 
initiating step, was due to the viral recognition of other immune cells, such as DCs. 
In the absence of cytokine production, the alteration of α4β7 expression on the 
purified T cells upon viral infection was barely observed. However, in purified T cells 
cultured with Sendai and EMCV virus, α4β7 expression was still moderately 
downregulated. This could be due to the few non-T cells (e.g. dendritic cells) in the 
purified T cell fraction, since the control CpG condition also showed a decrease of 
α4β7 expression, which should be abrogated on purified T cells. Another possibility is 
that the virus can still infect T cells. Consistent with this, it has been reported that 
EMCV and Sendai virus are able to be detected directly by T cells since they express 
the cognate receptors RIG-I and MDA-5 (Anz et al., 2010).  
Our blocking experiment could confirm the role of IFN-α and IL-6 in modulation of 
α4β7 expression upon Sendai and EMCV infection, respectively. However, additional 
cytokines could play a role, since the downregulation is not completely inhibited.  
 
5.1.4 Regulation of of α4β7 expression  
 
Our finding raised the question of how the modulation of α4β7 expression is 
regulated. The reduced availability of proteins on the cell surface can be affected by 
several mechanisms: shedding, endocytosis, transcription downregulation and a 
higher rate of protein degradation by proteasomes. Shedding is a process in which 
the protein is cleaved at their juxta-membrane region by matrix metalloproteinases, 
leading to the release of the extracellular part of the proteins to the environment 
(Huovila et al., 2005). Whereas this process is known to disengage growth factors, 
cytokines and mediators from their membrane-bound precursors, it also functions to 
downregulate protein expression on the cell surface. A prominent example is the 
shedding of L-selectin, which rapidly occurs upon activation on T cells (Jung and 
Dailey, 1990) but also on other immune cells (Kishimoto et al., 1989; Morrison et al., 
2010).  
 
Another mechanism is the endocytosis, which leads to the engulfment of cell surface 
proteins into the cells. Subsequently, proteins can either be sent to lysosomal 
degradation or recycled back to the cell membrane. There are different pathways that 
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mediate this process, the most common are the clathrin and the caveolin-dependent 
pathways. It has been described that generally integrins are internalized via the 
endocytosis pathways and one integrin can utilize several endocytic routes (Caswell 
et al., 2009). Moreover, integrins are commonly not degraded upon internalization but 
are transported back to cell surface (Caswell and Norman, 2006, 2008; Jones et al., 
2006; Pellinen and Ivaska, 2006).  
 
In case of α4β7, the endocytic route and re-transport to the cell surface is likely the 
possible mechanism since its downregulation is a transient state and the shedding 
mechanism would not present an efficient and energy-saving way for this recycling 
effect. Supporting this idea, Hernández-Caselles and coworkers demonstrate that 
T cell clones which recognize Staphylococcus enterotoxin B, downregulate α4β7 
expression and the decreased expression is abrogated in presence of an actin-
depolymerizing agent cytochalasin D, indicating the inhibition of the receptor-
mediated endocytosis (Hernández-Caselles et al., 1996; Lamaze et al., 1997). 
    
Since IL-6 and IFN-α seem to be able to downregulate α4β7 on naïve T cells directly, 
it would be interesting to scrutinize which factors in the signaling would induce 
endocytosis. Due to the fast transcriptional induction of interferon-stimulated genes 
(4-6 hours after type I IFN signaling activation) (Dondi et al., 2003), it is likely that 
endocytosis may be triggered by interferon-stimulated genes. 
 
5.1.5 Transient blockade into the GALT and to lesser extent into peripheral 
lymph nodes  
 
Supporting our finding in the alteration of α4β7 expression upon IFN-α stimulation, in 
our adoptive transfer experiment we observe a severe defect in migration into the 
Peyer’s patches. This supports the hypothesis that α4β7 downregulation on naïve 
CD8+ T cells influences their migration pattern. This correlates with the study of 
Wagner and coworkers, in which they demonstrated that the migration of β7-/- 
lymphocytes into the Peyer’s patches was almost abolished (Wagner et al., 1996) 
and this effect was even more pronounced when L-selectin/β7-/- lymphocytes were 
utilized (Wagner et al., 1998). Furthermore, their migration study reveals a less 
dramatic impact for the trafficking of β7-/- lymphocytes into MLN (49% reduction 
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compared to the wild-type lymphocytes). Consistently, in our study we observe that 
the migration of IFN-α-treated splenocytes into MLN is reduced by half compared to 
the wild type splenocytes.  
 
However, the reduction of L-selectin on CD8+ T cells upon IFN-α stimulation may 
also play a role in the observed result for MLN, since L-selectin act together with β7 to 
promote lymphocyte trafficking into MLN, which was confirmed by migration studies 
using L-selectin/β7-/- lymphocytes (Wagner et al., 1998; Dutt et al., 2005). 
Furthermore, IFN-α treatment causes a less significant reduced migration into the 
PLN, which is more likely due to the L-selectin downregulation (Warnock et al., 
1998).  
 
5.2 Physiologcal role of α4β7 downregulation 
 
It is tempting to speculate that α4β7 downregulation is implicated in the regulation of 
T cell proliferation, as it has been shown for L-selectin. A study by Nishijima et al. 
demonstrates that T cell proliferation induced by immobilized anti-CD3 was 
enhanced in presence of antibody against L-selectin (Nishijima et al., 2005). It is 
therefore tempting to speculate that the downregulation of α4β7 and L-selectin in 
presence of IFN-α would also be a mechanism to inhibit or reduce proliferation of the 
bystander-activated T cells. Supporting this idea, Marshall and coworkers 
demonstrate that proliferation of bystander-activated CD8+ T cells was suppressed 
upon viral infection, specifically due to type I IFN. Moreover, they show that this was 
due to a delayed onset of division that was an intrinsic defect of T cells (Marshall et 
al., 2011). Consistently, Nishijima and coworkers further reveal that the expression 
level of p27 on T cells, a cyclin-dependent kinase inhibitor, was decreased in 
presence of antibodies against L-selectin. Even more interestingly, p27 is shown to 
be increased in human naïve T cells treated with IFN-α prior to T cell activation 
(Dondi et al., 2003). Since we discover that α4β7 is downregulated upon IFN-α 
treatment, it would therefore be interesting to investigate whether the 
downmodulation of α4β7 contributes to the cell cycle inhibition due to the increase 
expression of p27. One possibility is to utilize T cells overexpressing α4β7 that do not 
downregulate α4β7 upon IFN-α treatment and compare p27 expression with 
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unmodified T cells that are sensitive toward IFN-α.  
 
The interpretation of the functional importance of the observed reduced migration is 
challenging. It could be that the reduced entry into the mesenteric lymph nodes and 
Peyer’s patches for bystander-activated T cells would provide space for effector 
T cells in the GALT to expand. Moreover, bystander-activated T cells are known to 
have an increased responsiveness to subsequent stimulation via TCR, thus lowering 
the threshold of activation (Alves et al., 2005; Gagnon et al., 2008). The impaired 
homing into the GALT during viral infection may therefore prevent an inappropriate 
T cell activation for these pre-activated T cells, which could lead to recognition of 
self-antigen, hence causing autoimmune diseases.  
 
Marshall and coworkers demonstrated that viral infection leads to a transient immune 
suppression and that this might contribute to the inability of a vaccine to elicit 
immunity (Marshall et al., 2011). A recent study showed that injection of poly (I:C) 
prior to antigen leads to a suppression of antigen-specific CD8+ T cell expansion and 
reduction of effector differentiation (Ngoi et al., 2012). Furthermore, it was shown that 
this is due to the downregulation of the IL-33 receptor subunit ST2 affecting the 
production of IFN-γ by CD8+ effector T cells. At the same time, IFN-γ and IL-33 might 
contribute to occurrence of inflammatory bowel diseases (Fasano and Shea-
Donohue, 2005; Seidelin et al., 2011). Interestingly, using systemic lung injury model 
they could show that the pretreatment with poly (I:C) and blocking ST2 could reduce 
the systemic accumulation of effector T cells thus limiting damage in the periphery.  
 
The impairment of T-cell effector differentiation by poly (I:C) pretreatment would 
explain on one hand the observation by Marshall and coworkers why a vaccine is not 
able to boost immunity when viral infection just occurred shortly prior to vaccination. 
On the other hand, the effect seemed to be a mechanism to prevent uncontrolled 
immune infiltration. Furthermore, the downregulation of α4β7 might contribute to the 
observed defect of CD8+ T cells. The transient blockade mechanism might prevent 
inappropriate activation bystander-activated T cells on early time point of infection but 
at the cost of excluding naïve CD8+ T cells from the GALT that would recognize an 
antigen of an invading pathogen in this time window. 
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Both studies of Marshall and Ngoi also additionally showed that co-injection of 
antigen and virus (or poly (I:C)) leads to an adjuvant effect, in contrast to the 
sequential injection causing immune suppression or defect response of CD8+ T cell. 
Since the adoptive-transfer study of Heidegger et al. was also performed by co-
injecting OVA and CpG or LPS simultaneously, it would be therefore interesting to 
investigate if there is a delay in α4β7 upregulation by OVA-specific T cells when 
sequential injection is performed.   
 
5.3 Therapeutical approach of T cells overexpressing α4β7 
 
In the second part of this project, we have cloned the integrin genes α4, β1 and β7 into 
retroviral vector to transduce them into primary T cells. De Nucci and coworkers 
demonstrate that overexpression of α4 leads to higher expression of α4β7 on the cell 
surface (DeNucci et al., 2010). The aim of our project is to increase α4β7 expression 
on T cells to improve targeting into gastrointestinal tumors. T cells are important in 
tumor rejection since they are able to recognize tumor-associated antigens, which is 
however often impeded by tumor immune evasion. TCR engineering to improve 
avidity of T cells towards these antigens is one of the promising strategies in the 
tumor immunotherapy field to overcome this evasion.  
However, a high efficacy of tumor eradication requires specific accumulation of these 
T cells in the tumor. Our study in SV40 tumor mouse model has demonstrated that 
adoptive transfer of tumor-specific T cells is highly effective in eradication of 
subcutaneous tumor, however they fail to eliminate autochtonous stomach tumor due 
to its immunosuppressive microenvironment (Bourquin et al., 2010). Therefore, 
breaking of the immunosuppression and selective homing of tumor-specific T cells 
into the tumor, thereby increasing accumulation of these T cells in the tumor, are 
crucial steps in refinement of tumor immunotherapy. Overexpression of cell adhesion 
molecules on T cells and also their ligands in the tumor would be strategies to 
enhance homing into the tumor.  
In our future study, we plan to investigate whether the overexpression of α4β7 on 
T cells would increase the infiltration of T cells into the SV40 autochtonous stomach 
tumor, in combination with increasing expression of MAdCAM-1 in the stomach 
tumor. Additionally, it would be interesting to analyze whether the stomach tumor 
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eradication is enhanced when α4β7 is overexpressed on T cells from TCR transgene 
mice that recognize specifically SV40 antigen. 
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5.4 Conclusion and outlook 
 
The migration of unspecifically activated naïve T cells in a viral infection has been 
poorly researched in contrast to the migration of virus-specific activated T cells. In 
our viral infection study utilizing poly (I:C), we discovered that the integrin α4β7 
expression on naïve CD8+ T cells was negatively regulated upon recognition of 
poly (I:C). Furthermore, we demonstrated that this effect was mediated by IFN-α. 
Consistently, studies with Sendai and VSVmut virus confirmed the role of IFN-α in its 
ability to control α4β7 expression. In the case of our study using EMCV virus, we 
demonstrated that IL-6 was the major cytokine that mediated the α4β7 
downmodulation. Finally, using an adoptive transfer model we demonstrated that 
migration of bystander-activated CD8+ T cells into the GALT, especially into the 
Peyer’s patches, was severely impaired upon exposure to IFN-α due to the 
downregulation of the α4β7 expression.  
The downregulation of α4β7 expression on the naïve CD8+ T cells and the 
subsequent reduced migration into the GALT might be a mechanism to prevent 
further inappropriate activation of the preactivated naïve CD8+ T cells in the GALT, 
as indicated by the upregulation of the early activation marker CD69 on these T cells. 
Consequently, this action could be a safeguard mechanism to avoid uncontrolled 
influx of unspecific T cells into the intestine, hence minimizing the risk of developing 
autoimmune diseases.  
In the second part of our project, we successfully cloned the integrin genes α4, β1 
and β7 into retroviral vectors. In transfection experiments we could further 
demonstrate that these retroviral vectors are functional, since we could detect higher 
expression of all integrins in the transfected retroviral packaging cell line (Plat-E 
cells). Finally, we could also observe more expression of α4 and β1 in the transduced 
primary T cells. However, transfection and transduction efficiency still need to be 
optimized.  
In tumor patients, very often the T-cell receptors (TCR) are poorly reactive toward 
tumor antigen. Modifications such as TCR engineering to achieve high specificity 
toward tumor antigens and the development of a chimeric immune receptor, a fusion 
of antibody domain with TCR chain to overcome MHC downregulation often 
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observed in tumors, are promising strategies to optimize the effectiveness of 
adoptive T cell transfer for tumor patients. Selective migration of these T cells into the 
tumor could serve as an additional improvement in the adoptive T cell transfer 
therapy. Our retroviral vectors might therefore be a promising tool to investigate 
whether overexpression of α4β7 enhances homing of tumor-specific T cells into 
gastrointestinal tumors and contributes to an improved tumor immunotherapy. 
Gastrointestinal tumor murine models such as the autochtonous SV40 stomach 
model and a pancreas tumor model expressing ovalbumin, are available in our 
laboratory for exploring the benefit of the α4β7 overexpression in the adoptive transfer 
model to treat tumors. The overexpression of α4β7 on T cells of existing transgenic 
mice, which specifically possess TCR against the antigen SV40 or ovalbumin, and 
the adoptive transfer of these T cells into the above-mentioned tumor murine models, 
are the next steps to verify the efficacy of this therapeutic strategy. 
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7 Appendices 
7.1 Abbreviations 
A  
APC Antigen-presenting cell 
AP1 Activator protein 1 
B  
BSA Bovine serum albumin 
C  
CCL Chemokine ligands 
CCR Chemokine receptors 
CD (e.g. CD3) Cluster of differentiation  
cDNA complementary DNA 
CFSE Carboxyfluorescein succinimidyl ester 
CLA Cutaneous lymphocyte antigen 
CTL Cytotoxic T cell 
CpG Oligonucleotide with cytosine-(phosphate)-guanine motifs 
D  
DAI DNA-dependent activator of IFN-regulatory factors 
DC Dendritic cell 
ddH2O Double-distilled water 
DMSO Dimethyl sulfoxide 
dsDNA Double-stranded DNA 
E  
EAE Experimental autoimmune encephalitis 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
EMCV Encephalomyocarditis virus 
F  
FACS Fluorescence-activated cell sorting  
FCS Fetal calf serum 
FSC Forward scatter 
G  
GALT Gut-associated lymphoid tissue 
H  
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HEV High endothelial venules 
HIV Human immunodeficiency virus 
HRP Horseradish peroxidase 
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I  
ICAM-1/2 Intercellular Adhesion Molecule 1/2 
IFN Interferon 
IFNAR Interferon-α/β receptor 
Ig Immunoglobulin 
IL (e.g. IL-2) Interleukin 
IRF Interferon regulatory factor 
ISGF3 Interferon-stimulated gene factor 3 
ISRE Interferon-sensitive response element 
J  
Jak1 Janus kinase 1 
L  
LB medium Lysogeny broth medium 
LFA-1 Lymphocyte function-associated antigen 1 
LMCV Lymphocytic choriomeningitis virus 
LPAM-1/α4β7 Lymphocyte Peyer's patch adhesion molecule 1 
LPS Lipopolysaccharides 
M  
MAdCAM-1 Mucosal addressin cell adhesion molecule 1 
MAVS Mitochondrial antiviral-signaling protein 
MDA-5 Melanoma Differentiation-Associated protein 5 
MEM-NEAA Minimum Essential Medium Non-Essential Amino Acids 
MHC Major histocompatibility complex 
MLN Mesenteric lymph node 
MOI Multiplicity of infection 
M-protein Matrix protein 
MyD88 Myeloid differentiation primary response gene 88 
N  
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NK cells Natural killer cells 
ns Not significant 
O  
OT-I Transgenic mice with ovalbumin specific CD8+ T cells 
OVA Ovalbumin  
P  
PCR Polymerase chain reaction 
PBS Phophate-buffered saline 
PAMPs Pathogen-associated molecular patterns 
PLN Peripheral lymph node 
PP Peyer’s patch 
PTK Protein tyrosine kinase 
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R  
RA Retinoic acid 
RALDH Retinaldehyde dehydrogenase 
RAR/RXR Retinoic acid receptor/retinoid X receptor 
RARE Retinoic acid response element 
RIG-I Retinoic acid inducible gene-I 
RPMI medium Roswell Park Memorial Institute medium 
RT Room temperature 
S  
SSC Side scatter 
ssRNA Single-stranded RNA 
STAT Signal Transducer and Activator of Transcription 
STING Stimulator of IFN-genes 
T  
TCR T cell receptor 
TECK/CCL25 Thymus-expressed Chemokine 
Th T helper 
TLR Toll-like receptor 
TMB 3,3’,5,5’-Tetramethylbenzidine 
TRIF TIR-domain-containing adapter-inducing interferon-β 
Tyk2 Protein-tyrosine kinase 2 
U  
UV Ultraviolet 
V  
VCAM-1 Vascular cell adhesion protein 1 
VLE Very low endotoxin 
VSV Vesicular stomatitis virus 
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7.2 Publications 
7.2.1 Original publications 
 
1. Efficient eradication of subcutaneous but not of autochthonous gastric tumors 
by adoptive T cell transfer in a SV40 T antigen mouse model (Journal of 
Immunology, 2010) 
Bourquin C, von der Borch P, Zoglmeier C, Anz D, Sandholzer N, 
Suhartha N, Wurzenberger C, Denzel A, Kammerer R, Zimmermann W, 
Endres S.  
Journal of Immunology, 2010; 185(4):2580-8. (Journal Impact Factor, JIF, 
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2. Cellular Immunostimulation by CpG-Sequence-Coated DNA Origami 
Structures. 
Schüller VJ, Heidegger S, Sandholzer N, Nickels PC, Suhartha N, Endres S, 
Bourquin C, Liedl T. 
ACS Nano. 2011 Dec 27;5(12):9696-702. (JIF 9.86) 
 
3. TLR activation excludes circulating naïve CD8+ T cells from gut-associated 
lymphoid organs in mice. 
Heidegger S, Kirchner SK, Bohn B, Suhartha N, Hotz C, Anz D, Sandholzer 
N, Rüssmann H, Endres S, Bourquin C. 
Journal of Immunology, in revision 
 
4. Virus-associated activation of innate immunity induces rapid degeneration of 
Peyer’s patches 
Heidegger Simon, Anz David, Bohn Bernadette, Stephan Nicolas, 
Suhartha Nina, Sandholzer Nadja, Kobold Sebastian, Hotz Christian, Radtke-
Schuller Susanne, Krug Anne, Endres Stefan, Bourquin Carole 
Manuscript in preparation 
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5. Viral infection modulates expression of the gut homing molecule α4β7 on naïve 
T cells.  
Suhartha Nina, Heidegger Simon, Sandholzer Nadja, Kirchner Sophie-
Kathrin, Bohn Bernadette, Stephan Nicolas, Fertig Marina, Endres Stefan, 
Bourquin Carole. 
Manuscript in preparation  
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